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ABSTRACT
Staphylococcus aureus is a colonizer of the human skin and mucosa that can
cause minor to severe disease. Originally afflicting patients at the extremes of age or
those with immunocompromising co-morbidities, S. aureus strains have emerged that
cause invasive disease in otherwise healthy populations with no health-care associated
risk factors. In addition, these community-acquired strains predominately contain
antibiotic resistance genes, making them difficult to treat with conventional interventions.
Invasive disease in S. aureus is partly regulated by a quorum sensing signaling system
that relies on the secretion and signaling function of a bacterial peptide pheromone (AIP).
S. aureus strains that lack this virulence regulator system still cause disease, but it is
much less severe and is typified by a colonizing, rather than an invasive, phenotype.
Therapeutics or host factors that inhibit virulence instead of viability can limit both
invasive disease as well as the development of resistance.
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During infection, the inflammatory process causes serum to extravasate into the
affected tissue site. Serum has been shown to inhibit virulence signaling in S. aureus,
though the mechanism is unknown. This dissertation identifies apolipoprotein B (apoB),
the major protein component of very low and low density lipoproteins, as a potent
inhibitor of virulence signaling in S. aureus by binding the bacterial signaling pheromone
AIP. Though binding of host lipoproteins to bacterial products has been described in
Gram-negative infections, this is the first demonstration of a lipoprotein component
having protective effects in a Gram-positive infection. This work further describes the
inhibitory action of apoB on virulence signaling and subsequent invasive infection in
multiple S. aureus strains and identifies the globular amino terminal domain of apoB as
the AIP binding site. These findings have important implications for understanding the
host-pathogen interaction and for developing therapeutics that can be effective without
causing bacterial resistance.
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CHAPTER 1
INTRODUCTION
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Pathogenicity of Staphylococcus aureus

Staphylococcus aureus, a colonizer of the human skin and mucosa, causes mild to
severe disease, ranging from localized skin and soft tissue infections to necrotizing
pneumonia or sepsis. A Gram-positive coccus, S. aureus derives its name from its
resemblance to a cluster of grapes when observed under the microscope, and from its
golden pigmented colonies. Over one third of the human population is permanently
colonized, while 60% are transiently colonized with this organism, predominately in the
nares and on the skin (Klevens et al., 2007). Colonization is a risk factor for infection,
though not an exclusive determinant of disease development or outcome (Ellis et al.,
2004; Wertheim et al., 2005).
S. aureus is a very genetically heterogeneous pathogen and strains are classified
by using pulsed field gel electrophoresis (PFGE) typing (Prevost et al., 1991). The
increase of resistance to methicillin, a penicillin family member, has led to the distinction
of methicillin resistant strains (methicillin resistant Staphylococcus aureus, MRSA) from
those that are methicillin sensitive (MSSA)(Sakoulas and Moellering, 2008). Of these,
PFGE types USA100, USA300, and USA400 are responsible for most MRSA disease in
the United States (Klevens et al., 2007). These MRSA isolates are typified by antibiotic
resistance, increased virulence factor production, and aggressive invasive disease (Baba
et al., 2002; Chambers, 2005). In the United States in 2005, the incidence of invasive
MRSA infection was 31.8 out of 100,000: greater than the incidence of all other invasive
bacterial infections combined. That same year, invasive MRSA disease caused more
deaths in the U.S. than did HIV/AIDS (Klevens et al., 2007).
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While S. aureus is typically an opportunistic pathogen causing infections in those
with chronic health conditions and at extremes of age, community acquired (CA) MRSA
infections have been described in otherwise healthy populations, including adolescents,
children in daycare centers, prisoners, and athletes (Miller et al., 2005)which have no
health care-associated risk factors (Deleo et al., 2010; Miller et al., 2005). CA-MRSA
strains do not evolve under antibiotic selection in a hospital setting, but rather among the
healthy public. Transmission for the CA-MRSA USA300 and USA400 strains is most
frequently skin-to-skin contact or contact with contaminated surfaces, as evidenced by
the populations affected, while hospital acquired disease (HA-MRSA) is generally caused
by patients’ colonizing strains gaining physiological access beyond the skin or mucosal
barrier (Wertheim et al., 2004; Wertheim et al., 2005).
Complicated disease from MRSA is of concern not only because of its virulence,
but also because of its resistance to standard antibiotic therapy. The development of
antibiotic resistance in S. aureus began in 1947 with the discovery of infections that were
resistant to penicillin treatment (Barber, 1947). Shortly thereafter, in 1961, resistance to
the penicillin family member methicillin was described (Barber, 1961). The resistance to
methicillin in the CA-MRSA strains seen today is due to the acquisition of a
staphylococcal chromosomal cassette SCCmecIV which contains the gene mecA that
encodes for specific resistance to β-lactam antibiotics including methicillin (Baba et al.,
2002). Though many infections with CA-MRSA should be treatable by other non-βlactam antibiotics, the diagnostic window for determining the antibiotic resistance profile
of any particular strain is inconsistent with providing timely treatment. Thus, patients are
often treated with powerful antibiotic regimens of intravenous vancomycin (Baba et al.,
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2002; Deleo et al., 2010). As a result, vancomycin resistant strains have been reported,
though rarely, probably due to the acquisition of vancomycin resistance genes from
Enterococcus faecalis (Chang et al., 2003). Since the standard treatment by antibiotics is
limited against MRSA regardless of its source, new treatment options that do not promote
the development of resistance need to be investigated and developed. One such option
involves understanding MRSA virulence as a potential therapeutic target. Since virulence
factors play a role in infection and clinical outcome, but not in bacterial viability, any
therapy or host defense against them is not expected to induce the development of
bacterial genetic resistance.

Quorum Sensing as a Regulator of Bacterial Virulence

Virulence factor production in S. aureus is highly regulated and dependent on the
growth phase, bacterial environment, and population density. The regulation of virulence
factors by sensing the environment and bacterial density, referred to as quorum sensing,
is a molecular mechanism of bacterial communication utilized by several bacterial
pathogens of humans (Parker and Sperandio, 2009). Common to these quorum sensing
systems is the use of an autoinducer pheromone that is released by the bacteria into the
environment; once the bacterial population and thus autoinducer concentration increases,
the bacteria respond by changing gene expression which results in a shift in the bacterial
life cycle, metabolism, and phenotype (de Kievit and Iglewski, 2000). Four quorum
sensing systems have been described so far based on their signaling molecules, receptors
and response regulators. Gram negative bacteria such as Vibrio fisheri and Pseudomonas
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aeruginosa synthesize N-acyl homoserine lactone (AHL) signaling molecules which (1)
diffuse across the bacterial membrane into the environment, (2) accumulate as bacterial
population increases, (3) diffuse back into the cell, and (4) bind its receptor, activating
the receptor to be a transcription factor for several downstream genes (Williams and
Camara, 2009).
A second, similar system relies on the production of a furanone that accumulates
in the environment before diffusing back into the periplasmic space of the cell, binding to
a transporter, entering the cell, and being phosphorylated. The phosphorylated
pheromone is then believed to bind to transcriptional repressors as well as act as a
transcription factor for downstream expression events to occur (Taga et al., 2001). This
second system has been observed in Escherichia coli, Salmonella Typhimurium, and
Streptococcus pyogenes among other both Gram-positive and Gram-negative species
(Lyon et al., 2001; Xavier and Bassler, 2003).
A third mechanism of quorum sensing has only been partially described in Gramnegative bacteria including Shigella, Klebsiella, and Salmonella species as well as nonpathogenic E. coli (Walters et al., 2006). This system relies on a third kind of
autoinducer, the structure and synthesis of which is unknown, that is recognized by the
sensor kinase QseC on the bacterial membrane which then phosphorylates the response
regulator QseB, activating it to exert its transcriptional regulation on downstream gene
targets (Parker and Sperandio, 2009).
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Quorum Sensing in S. aureus

The fourth quorum sensing system is found only in Gram-positive bacteria and
was originally characterized in S. aureus though it has been identified in Enterococcus
faecalis and Staphylococcus epidermidis (Qin et al., 2001; Van Wamel et al., 1998;
Yarwood and Schlievert, 2003). Quorum sensing in S. aureus is controlled by the
accessory gene regulator, or agr operon. This bacterial regulator operon has been well
characterized and it functions to control the expression of many virulence factors
associated with invasive MRSA disease (Cheung et al., 2002; Cheung et al., 2004;
George and Muir, 2007; Yarwood and Schlievert, 2003). The agr operon is a twocomponent sensor regulator system that consists of two divergent promoters, P2 and P3.
The P2 promoter drives the agrA,B,C,D genes and the P3 promoter induces RNAIII, a
regulatory RNA. When the P2 promoter is activated, the peptide AgrD is secreted
through AgrB as a cyclic thiolactone structure termed the autoinducing peptide (AIP, see
Figure 1A). Different S. aureus strains may express one of four different AIPs which
differ slightly in amino acid composition and overall length (see Figure 1B). The
thiolactone ring, however, is a common element and is essential for binding and signaling
through the AgrC receptor (Wright et al., 2004). The difference of AIP type allows S.
aureus strains to be further classified as agr types 1, 2, 3, or 4. These different AIPs are
mutually antagonistic to one another (Ji et al., 1997). Prevailing CA-MRSA strains USA
300 and USA 400 are agr groups 1 and 3, respectively, though all four types are
represented in human disease (Jarraud et al., 2002; Klevens et al., 2007).

(B) Sequences of the four different AIP structures found among S. aureus strains. All share a cyclic
thiolactone important for binding to the AgrC receptor. The amino-terminal residues are required for AIP
signaling through AgrC. Schematic adapted from George and Muir, 2007

(A) The P2 promoter encodes the agr signaling and response regulator proteins. AgrD is exported through
AgrB as the thiolactone AIP. Binding of AIP to AgrC activates the histidine kinase AgrA, which acts on the
P2/P3 promoter as well as the promoter for the toxin psmα. The P3 promoter induces transcription of
regulatory RNAIII, which acts on the promoters and translation initiation regions of several genes to
upregulate secreted proteins important for invasion and to downregulate adhesins. δ-hemolysin is also
transcribed from the RNAIII message.

Figure 1. The agr Quorum Sensing Operon in S. aureus
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When the AIP binds its receptor AgrC, a histidine kinase, AgrA is phosphorylated which
then acts on the P2/P3 promoter site to induce increased expression of the Agr genes and
begin expression of RNAIII (Novick, 2003). RNAIII itself is a 514 nucleotide transcript
with a secondary structure consisting of 14 hairpin stem loops. It functions primarily as a
regulatory RNA, but its 5ʹ-end encodes the gene for δ-hemolysin, a small cytolytic toxin,
the expression of which is controlled by the 3ʹ-end of RNAIII (Benito et al., 2000). When
autoinducer concentration is high, the resultant RNAIII goes on to act on the promoters
of several genes by either annealing to the promoters to expose their transcriptional start
sites, or interacting with the mRNA to occlude or expose ribosomal binding sites,
ultimately resulting in the downregulation of colonizing bacterial factors and the
upregulation of invading factors (George and Muir, 2007).
RNAIII acts as a master regulator to mediate a drastic phenotypic switch from
colonizing to invading. The gene targets regulated by RNAIII are classified as
colonization or invasion factors. Colonization factors include S. aureus protein A (spa)
which binds to IgG antibody, fibronectin binding protein (fbp), and clumping factors A
and B (clfA and clfB), all of which allow for adherence to tissues and the formation of a
biofilm phenotype. Invasion factors serve to disseminate the bacteria throughout the body
and include the cytolytic molecules alpha-hemolysin (hla) and Panton-Valentine
leukocidin (PVL) and proteases that destroy tissue. Other components of the S. aureus
arsenal which contribute to disease directly include toxins such as enterotoxins and toxic
shock syndrome toxin (TSST) (Yarwood and Schlievert, 2003). AgrA also acts directly
on the promoter of the psmα gene, which encodes phenol soluble modulin α, a cytolytic
peptide known to be highly expressed in CA-MRSA (Figure 1A) (Queck et al., 2008;

9
Wang et al., 2007). The importance of the agr quorum sensing system to virulence is
evidenced by the fact that bacterial strains lacking the agr operon are less virulent in
several animal models of infection. Conversely, the production of RNAIII at the site of
infection has been shown to be essential for acute invasive infection at the entry site
(Rothfork et al., 2003; Rothfork et al., 2004).
CA-MRSA strains, especially USA300, overproduce virulence factors regulated
by the agr system: alpha hemolysin, PVL, and psmα, in particular (Deleo et al., 2010).
The importance of PVL in CA-MRSA has been under debate, since PVL expression is
linked epidemiologically to human necrotizing pneumonia caused by USA300, but
experimental murine models showed no difference between wild type and PVL deletion
mutant strains (Bubeck Wardenburg et al., 2008; Gillet et al., 2002). Recently, however,
it has been shown that murine neutrophils are less sensitive to the PVL toxin, whereas
rabbit and human neutrophils lyse to a smiliar extent in response to PVL. In the context
of a more appropriate animal model, it is now clear that PVL does contribute to invasive
USA300 infection (Diep et al., 2010). USA300 has also acquired the arginine catabolic
mobile element (ACME), probably from S. epidermidis, which contains the gene for an
arginine deiminase, allowing the bacteria to better survive the acidic growth conditions of
the skin and thereby have increased fitness for transmission (Baba et al., 2002; Diep et
al., 2006). While both colonization and invasion factors are considered to be virulence
factors, those associated with invasive disease often cause the most dramatic and
damaging outcomes for the patient. The prevention of this phenotypic switch, therefore,
is of interest for treating patients with S. aureus infection.
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Host Immunity to S. aureus Infection

Although most adults have antibodies to S. aureus (Holtfreter et al., 2010), control
and clearance of infection relies on innate immune sensors and effectors rather than the
adaptive humoral response. Lipoteichoic acid, capsular polysaccharide, peptidoglycan,
and secreted bacterial proteins induce peripheral blood monocytes, epithelial cells, and
endothelial cells to produce IL-8, a potent neutrophil recruiting cytokine (Soell et al.,
1995; Standiford et al., 1994). Once neutrophils are recruited to the site of infection, they
sense bacterial products by Toll-like Receptor 2 (TLR2) (Kanneganti et al., 2007;
Takeuchi et al., 2000) or recognize host opsonins such as antibody or complement
proteins on the bacteria to induce phagocytosis. Upon phagocytosis, neutrophils destroy
the bacteria generally by oxidant-mediated killing (Fournier and Philpott, 2005). The
NADPH oxidase is activated upon bacterial phagocytosis and generates high levels of
superoxide anion, which quickly forms other reactive oxygen species like hydrogen
peroxide, singlet oxygen, and hypochlorous acid (Klebanoff, 1968; Rosen and Klebanoff,
1977). Mice lacking the NADPH oxidase are more susceptible to invasive S. aureus
infections than wild type controls, demonstrating the vital role this enzyme plays in host
defense (Rothfork et al., 2004). Intracellular killing also occurs by fusion of the
phagosome with cytoplasmic granules, containing antimicrobial peptides, α-defensins,
cathepsins, and other antimicrobial proteins which permeabilize pathogen membranes
(Ganz et al., 1985). The complement system also serves as a barrier to infection, causing
direct lysis of invading bacteria, opsonization and subsequent uptake by immune effector
cells, and recruitment of inflammatory cells to the site (Walport, 2001a; Walport, 2001b).
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The adaptive humoral immune system appears to provide limited control of S.
aureus infection despite increases of serum anti-staphylococcal antibodies (Holtfreter et
al., 2010). Antibodies found in the serum of patients reflect a robust response to the
staphylococcal antigens responsible for maintaining a colonizing phenotype, and they are
specific to the patient’s own individual colonizing strain of S. aureus. As such, the
antibodies have little activity against the invading virulent forms of the bacteria that
cause morbidity (Holtfreter et al., 2010). For these reasons, attempts at human
vaccination against S. aureus have failed despite successful animal vaccine studies
(Schaffer and Lee, 2009). Some adaptive immune system components, like Th17 cells,
have been shown to enhance innate immune phagocytic killing of S. aureus, leading Lin
and colleagues to develop a vaccine that specifically elicits a robust Th17 response which
can then drive effective neutrophil killing of bacteria in a mouse model of vaccination
and infection (Lin et al., 2009). It remains to be seen if this vaccine would be effective in
human cases of infection and if this strategy of eliciting a good PMN response by
vaccination will prove to be more effective than those focused on inducing humoral
immunity.

Bacterial Evasion of Host Immune Effectors

Notwithstanding the various immune mechanisms to clear infection, S. aureus has
developed numerous evasion methods in order to survive in the host (see Figure 2).
Serum immunoglobulin can opsonize the bacteria, but a secreted protease,
staphylokinase, activates host plasminogen on the bacterial surface, leading to cleavage
of surface-bound IgG as well as complement component C3b by the highly active
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protease plasmin (Rooijakkers et al., 2005b). S. aureus also produces an abundance of
inhibitors of complement activity, such as staphylococcal complement inhibitor (SCIN)
which stabilizes the C3 convertase to prevent deposition of C3b on the bacterial surface
(Rooijakkers et al., 2005a), and fibrinogen binding protein (Efb) and staphylococcal
binding protein (Sbi) which both block C3 accumulation on the cell surface (Burman et
al., 2008; Lee et al., 2004). Protein A, which is encoded by virtually all S. aureus strains,
binds to and immobilizes serum IgG, preventing the Fc portion from interacting with
receptors on inflammatory cells thus inhibiting subsequent phagocytosis (Foster, 2005).
Other bacterial surface-associated molecules such as capsule (Thakker et al., 1998) and
clumping factors A and B (Palmqvist et al., 2002) confer opsonic resistance and inhibit
phagocytosis as well. A secreted bacterial protein, chemotaxis inhibitory protein of S.
aureus (CHIPS), binds to the neutrophil receptors for chemotactic and migrationinducing molecules such as the complement anaphylatoxin C5a and bacterial formyl
peptide, slowing down the cellular response to infection (Postma et al., 2004). Reports
show that S. aureus can survive within the phagosome by preventing fusion with
azurophilic granules and escape the phagosome once inside neutrophils and multiply
rapidly in the intracellular environment (Gresham et al., 2000). Specialized bacterial
superoxide dismutases can prevent damage by the reactive oxidant species created by the
neutrophil NADPH oxidase (Liu et al., 2005). Secreted lytic factors are also in
abundance: alpha hemolysin, Panton-Valentine leukocidin, and phenol soluble modulins,
to name a few, which allow the
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Figure 2. Host evasion by S. aureus
S. aureus employs multiple mechanisms to evade host defense molecules, most of them
targeted at avoiding opsonization by complement, immunoglobulin, and fibrinogen and
phagocytosis by neutrophils. Other molecules are secreted to act directly on host cells.
Abbreviations: ClfA,B, Clumping factor A and B; PMN, Polymorphonuclear leukocyte;
ROS, reactive oxygen species; Hla, alpha-hemolysin; PVL, Panton-Valentine
Leukocidin; PSM-α, phenol soluble modulin α; Hlg, gamma-hemolysin; Efb, fibrinogen
bindng protein; Sbi, staphylococcal binding protein; SCIN, staphylococcal complement
inhibitor; Spa, staphylococcal protein A; CHIPs, chemotaxis inhibitory protein of S.
aureus.
Figure modified from Foster, 2005.
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bacteria to escape from intracellular compartments and whole host cells alike (Gillet et
al., 2002; Li et al., 2009; Menestrina et al., 2003). The host, therefore, must have multiple
layers of defense in order to contain infection.

The Acute Phase Response and the Role of Serum Lipoproteins in Infection

An important mechanism the body has to respond to infection, inflammation, and
trauma is the acute phase response. Hepatocytes respond to inflammatory mediators and
serum cytokines produced by injured tissue and leukocytes during inflammation and
infection by increasing the production of numerous serum proteins, including C reactive
protein (CRP) and complement proteins, and decreasing others such as albumin and
alpha-fetoprotein (Baumann and Gauldie, 1994; Gabay and Kushner, 1999). The most
dramatic alteration in serum concentrations of the acute phase proteins occurs 1-2 days
following the inflammatory stimulus, begins to resolve within days, and completely
returns to normal levels by 4 weeks (Gabay and Kushner, 1999). The presence of these
acute phase response proteins in the serum indicates ongoing inflammation and can be
useful in the diagnosis and treatment of patients. They also participate in host defense, by
opsonizing invading pathogens as is the case with complement proteins, and CRP has
several functions including: opsonizing bacteria for clearance by phagocytic cells,
stimulating inflammatory cytokine release, and downregulation of neutrophil activity
(Gabay and Kushner, 1999). Despite these beneficial functions, a persistant acute phase
response can lead to anemia, hypoalbuminemia, and secondary amyloidosis, while an
overactive acute phase response can contribute to septic shock (Gabay and Kushner,
1999).
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Serum lipids and lipoprotein levels are also altered during the acute phase
response, with varied and sometimes conflicting reports of the direction and degree of
alteration (Khovidhunkit et al., 2004; Sammalkorpi et al., 1988). Most studies agree that
total cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL)
serum levels decrease during acute infection or inflammation (Khovidhunkit et al., 2004).
Plasma triglyceride levels increase during sepsis, but not following trauma or surgery
(Alvarez and Ramos, 1986; Carpentier and Scruel, 2002). All these changes are often the
opposite in rodent models of infection, making them difficult to study in rodent models of
human disease (Sammalkorpi et al., 1988).
Alterations in serum lipoproteins during the acute phase response could have
great impact on the outcome of severe infection, since they have been identified as
having a role in host defense, especially against Gram negative pathogens, by binding
and neutralizing lipopolysaccharide (LPS) (Barcia and Harris, 2005; Feingold et al.,
1995; Harris et al., 1990; Harris et al., 1993; Read et al., 1995). The protein components
apoA-1 (found on HDL) and apoE (found on LDL, HDL, and chylomicrons) have
specifically been shown to inactivate LPS in vitro while apoE–deficient mice are more
susceptible to Gram negative infections (de Bont et al., 1999; Emancipator et al., 1992;
Flegel et al., 1993). The interplay of lipoproteins and Gram positive pathogens, including
S. aureus, has been less well characterized, though studies indicate that lipoproteins bind
lipoteichoic acid in a manner similar to the LPS-binding activity described above (Levels
et al., 2003). Importantly, our work included below describes a novel role for
apolipoprotein B of VLDL and LDL in host defense against quorum sensing S. aureus
infections.
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In light of these immunity-promoting properties, the decrease of LDL serum
concentrations during the acute phase response could have detrimental effects on the
host. This decrease is usually due to retention in the tissues by the LDL receptor or the
reduced activity of the lipoprotein lipase that converts very low density lipoprotein
(VLDL) into LDL (Carpentier and Scruel, 2002; Khovidhunkit et al., 2004). The relative
VLDL concentration is therefore increased in serum, tipping the balance even more in
favor of high triglycerides and low cholesterol content (Khovidhunkit et al., 2004; Marik,
2006). Further studies concluded that inflammatory cytokines reduce both total LDL and
its associated protein apolipoprotein B (apoB) in the serum of treated subjects and also in
the supernatant of human hepatic cells in culture (Ettinger et al., 1994; Schectman et al.,
1992). The decrease in serum lipoproteins is correlated with poor outcomes in septic
patients (Gui et al., 1996; Marik, 2006), leading us to further investigate how lipoproteins
may be important in host defense beyond what has previously been described.

Lipoproteins: Synthesis and Function in the Host

Serum lipoproteins are heterogeneous particles made up of a core of triglycerides
and cholesterol esters surrounded by a layer of phospholipids and unesterified
cholesterol. Protein components are added to the particles either during formation or after
secretion from hepatocytes (Mahley et al., 1984; Segrest et al., 2001; Shelness and
Sellers, 2001). Different classes of lipoproteins are distinguished by their density,
composition, and function. LDL and VLDL transport triglycerides and cholesterol from
the liver to the tissues for use in metabolism. HDL is responsible for clearing
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triglycerides and cholesterol from the circulation for recycling or excretion in the liver.
Apolipoprotein B (apoB) is a large (4536 amino acid), amphipathic lipid binding protein
found in the serum associated with LDL and VLDL. The pentapartite structure is
composed of a globular amino terminus, two domains of beta pleated sheets, and two
alpha helical domains that span the entire surface of the lipoprotein particle (Segrest et
al., 2001) (see Figure 3A). Unlike other apoproteins which are nonstructural and
exchangeable among lipoprotein particles, apoB is a non-exchangeable, structural
component of both LDL and VLDL (Segrest et al., 2001). ApoB synthesis initiates
assembly of the very low density lipoproteins in the endoplasmic reticulum, maturing
into the particle as lipid droplets fuse into the triglyceride core before being secreted from
the hepatocytes. Unlike apoB, other apoproteins do not share this assembly function;
rather, they are added to the particles after secretion (Mahley et al., 1984). Following
secretion, lipoprotein lipase (Lpl) metabolizes the VLDL, removing some of the lipids to
form LDL particles (Figure 3B). The synthesis of VLDL and subsequent metabolism is
depicted in Figure 3, the properties of all lipoprotein particles are summarized in Table 1.
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Figure 3. Synthesis, Structure, and Metabolism of Apolipoprotein B-containing
Particles
(A) Synthesis of VLDL is initiated by the translation of the apoB message into the lumen
of the endoplasmic reticulum. The Microsomal Triglyceride Transfer Protein (MTP)
functions to mediate lipid droplet formation from cytosolic lipids and also to transfer
lipids to the growing lipoprotein particle. Additional lipid droplets fuse with the precursor
particle to form the complete VLDL before it is secreted by the hepatocyte and into the
circulation. The pentapartite domain structure of apoB is shown wrapping around the
lipid core.
(B) In the circulation, apolipoproteins C and E (green) are transferred from HDL to
VLDL which already contains apolipoprotein B (pink). Lipoprotein lipase (LPL) removes
lipid components from VLDL to form the smaller, denser LDL particle. LDL and the free
lipid components are absorbed by the tissues for use in metabolism. Excreted cholesterol
is carried on HDL to the liver for excretion or recycling.
Figure adapted from Shelness and Sellers, 2001 and the American Oil Chemists’ Society
webpage (http://lipidlibrary.aocs.org/Lipids/lipoprot/index.htm).
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Table 1-Properties of Serum Lipoproteins
Particle

Size

HDL

~8 nm

Protein
composition
apoA-I,
apoA-II,
apoE,

LDL

~20 nm

apoB100

VLDL

30-90 nm

apoB100,
apoC-I, apoCII, apoC-III,
apoE

Lipid composition

Function

Phosphatidylcholine
(40%), choleseryl ester
(30%)

Transport
cholesterol
from tissues to
liver
Transport
cholesterol and
triglycerides to
tissues from
liver

Cholesteryl esters (50%),
phospholipids (30%),
unesterified cholesterol
(10%), triglycerides
(10%)

Triglycerides (55%),
Transport
phospholipids
cholesterol and
(20%),unesterified
triglycerides to
cholesterol (10%)
tissues from
esterified cholesterol
liver
(5%)
Chylomicrons 200-600
apoB48,
Triglycerides (85%),
Transport
nm
ApoA-I,
phospholipids
cholesterol and
apoC-I, apoC(8%),unesterified
triglycerides to
II, apoC-III
cholesterol (2%)
tissues from
esterified cholesterol
intestine (diet)
(3%)
Sources: Black, 2007; Morrisett et al., 1975, and the American Oil Chemists’ Society
webpage (http://lipidlibrary.aocs.org/Lipids/lipoprot/index.htm).
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ApoB is necessary for lipoprotein particle binding to the LDL receptor, which is
found on all nucleated cells and is necessary to the provision of essential lipids required
for normal cell and organ function. LDL also binds to scavenger receptors found on
macrophages. These scavenger receptors recognize modified low density lipoproteins
such as acetylated LDL (ac-LDL) and oxidized LDL, which are associated with
atherosclerosis (Henriksen et al., 1981; Henriksen et al., 1983). Some of these receptors
play important roles in host defense. Particularly for S. aureus, CD36 is important for
both sensing in combination with TLR2 a lipid derivative of this pathogen and directly
for phagocytosis of this pathogen. Thus, multiple components of lipoprotein metabolism
interact to contribute to host defense against S. aureus infections.

Summary and Hypothesis

The rise of antibiotic-resistant strains of S. aureus that cause severe invasive
infection highlights the need to understand and develop alternative strategies for therapy.
One such strategy is to target virulence instead of viability, thereby reducing the chance
for development of resistance. The agr system of virulence regulation, or quorum
sensing, is a good target since agr mutants are drastically attenuated in their virulence. A
few host defense mechanisms against quorum sensing signaling pheromones have been
described in recent years, including oxidant modification of S. aureus AIP (Rothfork et
al., 2004) and cleavage of the P. aeruginosa AHL (Chun et al., 2004; Ozer et al., 2005).
Neutrophil-derived oxidants effectively inactivate agr type 1 S. aureus AIP by oxidizing
the C-terminal methionine residue (Rothfork et al., 2004). However, as described above,
bacterial neutrophil escape mechanisms are varied and abundant. Work in our group
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indicates that normal serum lipoproteins inhibit quorum sensing in vitro. Since serum
components extravasate into an infected tissue site along with infiltrating leukocytes, we
hypothesized that serum lipoproteins serve as an innate barrier to agr-dependent S.
aureus infection. To address this hypothesis, we focused on apolipoprotein B as the main
inhibitory component of serum lipoproteins and pursued the following specific aims: 1)
to define the role of apolipoprotein B as a specific barrier to quorum sensing signaling in
agr type 1 strains both in vitro and in an experimental animal model of skin infection; 2)
to define the role of apoB in control of agr signaling from agr2 and agr3 strains; and 3)
to define the role of the amino terminal domain of apoB in control of agr signaling. We
show that apoB demonstrates protective action against invasive disease by binding and
sequestering the AIP1 signaling peptide away from its receptor, thus preventing quorum
sensing-mediated virulence. We present preliminary data that this mechanism of control
is limited against agr3 S. aureus strains which predominate as causes of blood stream
infections and that several approaches demonstrate that the amino terminal domain of
apoB is sufficient to control agr1 signaling. These data represent the first demonstration
of apoB as a host defense barrier and describe a novel mechanism for control of invasive
infections in contrast to colonization.
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CHAPTER 2
METHODS

23

Reagents
Synthetic AIPs were generated as follows and stored in DMSO at -80°C: cyclic AIP1
(YSTC[→M]DFIM[→C]), FITC-AIP1, and biotin-AIP1 were synthesized by
Commonwealth Biotechnologies, Inc., Richmond, VA, and cyclic AIP1, cyclic AIP2,
cyclic AIP3 FAM-AIP2, and biotin AIP1 were synthesized byb Biopeptide Co., Inc. San
Diego, CA using a described method (Otto et al., 1998). Cyclic AIP 2
(GVNAC[→F]SSLF[→C]), AIP4 (YSTC[→M]YFIM[→C]), and AIP3 antagonist
(YINC[→L]DFLL[→C]) were generated as described (Otto et al., 1998). A disulﬁde
linked cyclic peptide, C(→C)LLRMKSAC(→C), was used as a control. Linear AIP1 and
biotin-AIP1 were generated by alkaline hydrolysis and neutralization. The following
reagents and sera were obtained as indicated: puriﬁed human VLDL, LDL, HDL, apoB,
apoA1, apoC1, and apoE (US Biological, Swampscott, MA); puriﬁed VLDL, LDL, AcLDL, DiI-Ac-LDL, and DiI-LDL (Biomedical Technologies Inc., Stoughton, MA);
pooled human serum, lipoprotein-deﬁcient serum, chicken serum, tributyrin, 4aminopyrazolo-(3,4-D) pyrimide (4APP), DL-Dithiothreitol, Iodoacetamide, Dimethyl
pimelimidate dihydrochloride, Pepstatin, trypsin soybean inhibitor, V8 protease,
thrombin and a liposome preparation reagent containing cholesterol, phosphatidyl
choline, and stearylamine (Sigma-Aldrich, St. Louis, MO); Pepsin (EMD-Calbiochem,
Gibbstown, NJ), 4-12% Tris-HCl Ready gels, Precision Plus Protein Standard, and Silver
stain kit (Bio-Rad, Hercules, CA), cholesterol and phosphatidylcholine (Avanti Polar
Lipids); polyclonal goat IgG anti-human apolipoprotein B 100 (R&D Systems,
Minneapolis, MN); monoclonal murine IgG1 anti-human apoB C1.4 (Santa Cruz
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Biotechnology, Santa Cruz, CA); and monoclonal murine IgG1 anti-human apoB 4C11
(Biodesign International, Saco, ME).

Bacterial Strains
S. aureus strains used in these studies were as follows: ALC 1743 (agr group 1 RN6390
containing reporter agr:P3-gfp), ALC 1740 (RN6390 containing reporter hla-gfp), ALC
1753 (RN6911 agr deletion mutant of RN6390 containing reporter agr:P3-gfp). RN6390,
SH1000 (σB corrected RN6390) , ALC 1225 geh- (strain 8325-4 with geh deletion
mutant with reduced lipase secretion) (Kupferwasser et al., 2003; Rothfork et al., 2004),
and USA100 strain 502A (agr group 2 clinical isolate). USA300 strain UAMS1378 and
its agr deletion mutant UAMS1540 were provided by Dr. Mark Smeltzer (University of
Arkansas), and USA300 strain LAC and its agr deletion mutant were provided by Dr.
Michael Otto (NIAID). USA400 strain MW2 and its agr deletion mutant were also
provided by Dr. Otto. Clinical isolates of CA-MRSA agr group 1 USA 300 (NM 300)
and agr group 3 USA 400 (NM 400) were provided by Dr. Steve Young, Department of
Pathology, University of New Mexico, and USA 300 strain FPR 3757 was provided by
Dr. Francoise Perdreau-Remington, UCSF.

Preparation of Bacterial Cultures
Primary stocks of all bacterial strains were prepared as followed: 25 ml of Columbia or
Trypticase Soy Broth (TSB, prepared with antibiotics as necessary, see below) in a 50 ml
Falcon tube was inoculated with either a 1:2500 dilution of original stock or a colony
from an original culture, loosely capped, and incubated at 37°C with shaking at 200 rpm
overnight. Cultures were centrifuged at 3000 rpm for 4 minutes at 4°C and washed twice
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with 10 ml of sterile saline. The pellet was resuspended in 5 ml of broth and two 1:84
dilutions of this culture were prepared in two 50 ml Falcon tubes containing broth and
antibiotics as necessary. Cultures were loosely capped and incubated at 37°C with
shaking at 200 rpm for 6 hours. Following incubation, the cultures were centrifuged and
washed with 5 ml saline per tube as above. The two cultures were combined during a
second wash with 10 ml of saline before pelleting a final time. The bacteria were
resuspended with 2 ml of broth containing 10% glycerol, placed on ice, and subjected to
two bursts of sonication for 5 seconds each. Stock was then aliquoted into vials
containing 100 µl each and then stored at -80°C. Strains requiring antibiotic selection and
the final concentration of antibiotic needed were: ALC1743 (10 μg/ml Chloramphenicol),
ALC 1740 (10 μg/ml Chloramphenicol), ALC1753 (10 μg/ml Chloramphenicol, 4 μg/ml
Tetracycline), UAMS1540 (2 μg/ml Minocycline), LAC Δagr (4 μg/ml Tetracycline).
To generate synchronized early exponential phase, nonfluorescent (where applicable)
bacteria, frozen stocks were cultured either in Columbia or Trypticase soy broth at a
1:2500 dilution in one 50 ml Falcon tube overnight at 37°C with shaking at 200 rpm. The
overnight culture was then washed three times with sterile saline in 20 or 10 ml volumes,
diluted 1:1000 in one Falcon tube and grown for 2 hours at 37°C with shaking at 200
rpm. Two hour growths were repeated twice more, with washing at the end of each 2
hour growth period, and cultures diluted first 1:84 into two tubes and finally 1:125 into
eight tubes (ALC strains) or four tubes (all other strains). At the end of the three two hour
growth periods, the cultures were combined into one tube with saline during the washing
and then ultimately resuspended in 2 ml of broth/10% glycerol, sonicated as described
above, and aliquoted 100 µl per cryovial and stored at -80°C. The titer of each stock was
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determined after the vials had been frozen 20 minutes-24 hours by resuspending the
frozen pellets of three vials with sterile saline to a volume of 1 ml each, centrifuging in a
microcentrifuge at 4°C for 4 minutes at a speed of 12,500 rpm. After discarding the
glycerol-containing supernatant, the pellets were resuspended in fresh saline to a volume
of 1 ml each, each vial was sonicated and then serial dilutions of the stock were plated on
blood agar.

Bacterial Promoter Activation Assays
Early exponential phase, nonﬂuorescent reporter bacteria (ALC1743 and ALC1740) (2 ×
107/ml) were incubated in 1 ml TSB in polystyrene tubes with shaking (200 rpm, 37°C)
for three hours or as indicated in the text. Alternatively, the bacteria were grown in 100
µl TSB in the wells of a 96-well round bottomed plate and placed on a Nutator at 37°C
for three hours. Samples included vehicle control, synthetic AIP1 at the concentrations
indicated or AIP1 treated with antagonists as referenced in the text. After incubation,
bacteria were washed by centrifugation at 3000 rpm for 4 min at 4°C in PBS with 0.1%
Triton X-100, sonicated, cultured for CFU, and then ﬁxed with 1% paraformaldehyde
containing 25 mM CaCl2 for analysis by ﬂow cytometry (FACSCalibur, Becton
Dickinson, Franklin Lakes, NJ or Accuri C6, Accuri Cytometers, Inc., Ann Arbor, MI ).
Promoter activation was demonstrated as ﬂuorescence induction and measured as the
mean channel ﬂuorescence (MCF) of GFP-positive bacteria.

Quantitative RT-PCR
Early exponential phase bacteria (2 × 107/ml, or as indicated in the text) were cultured as
above with the indicated AIP stimulation or treatment for the timepoints described in the
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figures. Bacterial RNA for RNAIII or psmα was quantified relative to 16S RNA using a
probe-based assay as described with minor modifications (Sawires and Gresham, 2008).
RNA was isolated and purified using the Qiagen RNAprotect Bacteria Reagent and
RNeasy Mini Kit, Protocol 3 with mechanical (sterile 0.1 mm zirconia silica beads,
Biospec, Bartlesville, OK) and enzymatic disruption by Proteinase K (Qiagen, Valencia,
CA). Contaminating DNA was removed by an on-column DNase treatment. cDNA was
generated from purified RNA using a high capacity cDNA RT kit with an RNase
inhibitor (Applied Biosystems, Foster City, CA) and a PTC-100 thermocycler (MJ
Research Inc., Watertown, MA). Thermal cycling conditions were as follows per the kit
instructions: 10 minutes at 25°C, 120 minutes at 37°C, 5 seconds at 85°C, hold at 4°C.
Quantitative PCR was done using an ABI7300 or ABI7500 Real-Time PCR system with
Taqman Gene Expression master mix, ROX probe/quencher, and appropriate primer
sequences (Applied Biosystems). Each experiment was performed in duplicate and
samples assayed in triplicate. Relative quantification of S. aureus RNA III was
determined by the change in gene expression relative to 16S gene expression. As a
control, no RNAIII was detected in the agr deletion mutant RN6911. Cycling conditions
were 2 minutes at 50°C, 10 minutes at 95°C, and 40 cycles of 15 seconds at 95°C with 1
minute at 60°C. The primer-probe sequences used were as follows: rnaIII forward primer
5ʹ-AATTAGCAAGTGAGTAACATTTGCTAGT-3ʹ, rnaIII probe 5ʹ-6-FAMAGTTAGTTTCCTTGGACTCAGTGCTATGTATTTTTCTT-BHQ-2-3ʹ, rnaIII reverse primer 5ʹGATGTTGTTTACGATAGCTTACATGC-3ʹ, psmα forward primer 5ʹ-TATCAAAAGCTTAATCGAACAATTC-3ʹ, psmα probe 5ʹ-6-FAMAAAGACCTCCTTTGTTTGTTATGAAATCTTATTTACCAGBHQ-2-3ʹ, psmα reverse primer 5ʹ-CCCCTTCAAATA-
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AGATGTTCATATC-3ʹ, 16S forward primer 5ʹ-TGATCCTGGCTCAGGATGA-3ʹ, 16S
probe 5ʹ-6-FAMCGCTGGCGGCGTGCCTA-BHQ-2-3ʹ, 16S reverse primer 5ʹ-TTCGCTCGACTTGCATGTA-3ʹ.

Virulence Factor Assays
Lipase and alpha hemolysin were measured in 0.45 µm filtered cultured supernatants
from bacterial strains grown as above in TSB with and without the relevant AIP or AIP
treated with various antagonists. Lipase (7 hr of culture) was measured as described using
a triglyceride substrate, tributyrin (Smeltzer et al., 1992). The tributyrin emulsion was
prepared in sterile lipase buffer (100 mM Tris pH 8.0, 25 mM CaCl2) by adding
Tributyrin (Sigma 113026-50G) to a final concentration of 0.5% and then subjected to 3
minutes of sonication at 40W. Separately, a 0.8% solution of low-gelling temperature
agarose was prepared in sterile lipase buffer with heating to dissolve and kept at 50°C
until use. The tributyrin emulsion and agarose solutions were then combined in equal
volumes for use in the assay. Lipase activity was observed by measuring the OD450 of the
a 1:10 mixture of supernatant:tributyrin substrate every 2 minutes for 12 minutes and
then plotted as optical density versus time.
Alpha hemolysin (6.5 hr of culture or as indicated) was measured as described using
rabbit erythrocyte lysis (Bernheimer, 1988). Rabbit erythrocytes (CS1081, Colorado
Serum Company) were washed in PBS twice by centrifugation at 3200rpm for 10
minutes at 4°C to remove Alsever’s preservation buffer. Erythrocytes were then
resuspended in PBS to a final concentration of 4% erythrocytes. Serial dilutions of the
sample supernatants were then mixed in equal volumes with the erythrocyte suspension
in a 96 well round bottom plate and incubated for 1 hour at 37°C. Following incubation,
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the plate was centrifuged for 3 minutes at 3800 rpm at 4°C and the supernatants were
transferred to a new 96 well plate and then read on a spectrophotometer at a wavelength
of OD450 nm. The lysis by the individual samples was compared to the total lysis of
erythrocytes that resulted from mixing equal volumes of the blood suspension and
PBS/0.1% Triton. One unit of hemolytic activity was defined as the amount of bacterial
supernatant able to liberate half of the total hemoglobin from the erythrocytes.

AIP Binding Assay
Early-exponential phase S. aureus (RN6390 or LAC at 2 × 107 cfu/ml) were incubated in
1 ml TSB in polystyrene tubes without shaking for 1 hour at 37°C. Cultures were
incubated in the presence of 1 µM FITC-AIP1 or control FITC-IgG alone or in
combination with 2 µg/ml VLDL, 10 µg/ml apoB, 10 µg/ml apoA1, or 1 µM native
AIP1. PBS was used as a vehicle control. Following incubation, samples were washed
and then fixed in 1% paraformaldehyde/25 mM CaCl2. Binding of FITC-AIP1 to the
bacteria was determined by flow cytometry.

Surface Plasmon Resonance
Surface plasmon resonance was performed with the Biacore X100 (Biacore Life
Sciences, GE Healthcare, Piscatawy, NJ) to analyze the interaction of apoproteins with
immobilized AIPs. N-terminal biotinylated AIP1, AIP2, AIP3, or Y-AIP3 in the native or
linear conformation as indicated in the figures were immobilized on streptavidin sensor
chips according to the manufacturer's protocol. The chips were regenerated with 50 mM
NaOH, 1 M NaCl and then washed with immobilization buffer (10 mM Hepes, pH 7.4,
150 mM NaCl, 3 mM EDTA). The biotinylated AIPs were pulsed onto the chip at 30
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µg/ml for 420 s at a flow rate of 10 µl/min followed by extensive washing. For binding
studies, the analytes (apoB, apoA1, apoC1, VLDL and LDL) at 10 nM in running buffer
(10 mM Hepes, pH 7.4, 250 mM NaCl, 3 mM EDTA) were applied at a flow rate of 10
µl/min with a contact time of 60 s and a dissociation time of 60 s. Chip platforms could
be regenerated to permit additional binding studies after a 60 s wash with 0.5% SDS
followed by 120 s stabilization period. For each experiment specific binding was
measured as the RU generated by analyte binding to the test surface minus RU generated
by analyte binding to the reference surface (streptavidin without biotin-AIP). Kinetic data
for apoB binding to biotin-AIP1 were collected at a flow rate of 30 µL/min with
association measured at 60 s and dissociation measured over 300 s. The Biacore
evaluation software (X100 Version 1.0) was used to analyze the results. For competition
studies, 50 nM soluble inhibitor peptides (AIP1, linear AIP1, AIP2, AIP4, YAIP3,
oxidized AIP1) in running buffer with 1% DMSO were incubated with 10 nM apoB prior
to injection over immobilized AIP1. Binding was measured at a flow rate of 10 µL/min
with contact and dissociation times of 60 s. All analyses were performed at 25°C.

Macrophage Uptake of AIP-LDL Complexes
RAW264 murine macrophage cell line (ATCC, Manassas, VA) was maintained in
Dulbecco’s Modified Eagle Media supplemented with L-glutamine,
penicillin/streptomycin (Gibco, Carlsbad, CA), and 5% lipoprotein-deficient fetal calf
serum (Sigma-Aldrich Co. St. Louis, MO). Cells (1 × 106) were incubated in suspension
in polystyrene tubes in 1 ml of serum-free, phenol red-free DMEM containing either 1
µg/ml DiI-Ac-LDL plus 9 µg/ml Ac-LDL or 10 µg/ml Ac-LDL at 4°C for 30 minutes.
Following incubation, 1 µM FITC-AIP1 or FITC-streptavidin was added, mixed gently,
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then placed at 37°C for 10 or 30 minutes. For controls, AcLDL was incubated with mAb
anti-apoB on ice for 30 min prior to addition to the cells. In addition, 1 µM FITC-AIP1
and 10 µg AcLDL were incubated on ice for 1 hr and then dialyzed prior to addition to
the cells. Following treatment, cells were washed twice in buffer, fixed with 3%
paraformaldehyde for 10 minutes, rinsed and resuspended in PBS. Cytospins were made
using a Shandon Cytospin 3 (Thermo Scientific, Waltham, MA), and coverslipped with
Prolong Gold anti-fade. Images were acquired on a Zeiss LSM 510 confocal microscope
and the percent co-localization of green and red fluorescence determined using Slidebook
software (Intelligent Imaging Innovations, Denver, CO).

Secretion of Human ApoB by Rat Hepatoma Cell Lines
McArdle-RH7777 cells stably transfected with constructs for human apoB-100, apoB-48
and apoB-17 have been provided by Zemin Yao, University of Ottawa, CA. Nontransfected control McArdle-RH7777 cells were purchased from ATCC (Manassas, VA).
All cells were maintained in Dulbecco’s Modified Eagle Media (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal calf serum (Gibco, Carlsbad, CA) , 10% horse serum
(VWR, West Chester, PA), 1%HEPES, and 1% penicillin/streptomycin in tissue culture
treated 75 cm2 flasks (Corning, Corning, NY). Transfected cell lines also received 0.2
mg/ml G418-sulfate (VWR, West Chester, PA). Sub-culture ratios were 1:4; cells were
rinsed with 1X PBS and detached with 0.05% Trypsin-EDTA (Gibco, Carlsbad, CA)
before removal and division among fresh flasks. To stimulate secretion of apoB, cells
were incubated for two days in serum-free media containing 0.2 mg/ml G418-sulfate.
Supernatants were collected and concentrated using Amicon Ultra-15 Centrifugal filter
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devices (Millipore Billerica, MA ), supplemented with an EDTA-free protease inhibitor
(Roche, Indianapolis, IN) and stored at 4°C .

Isolation of McArdle Cell-derived ApoB fragments
A murine monoclonal antibody C1.4 (Santa Cruz Biotechnology, Santa Cruz, CA) was
immobilized onto Protein G agarose beads (Thermo Scientific, Waltham, MA) following
a modified protocol from (Schneider et al., 1982). Beads (500 µl weight/volume) were
washed twice in a 0.1 M Sodium Borate solution and then combined with 200 μg of
antibody and incubated for 30 minutes at room temperature with gentle shaking. Beads
were pelleted by centrifugation and the supernatant removed and reserved. The beads
were then washed three times with borate buffer and once with 0.2 M triethanolamine.
Beads were then incubated for 45 minutes at room temperature with gentle shaking in a
solution of 25 mM Dimethyl pimelimidate dihydrochloride (Sigma, St. Louis, MO) made
up in 0.2 M triethanolamine, pH 8.2. Beads were then washed with 0.1 M ethanolamine
and then incubated 1 hour at room temperature with gentle shaking in fresh ethanolamine.
Following incubation, beads were washed three times in 1X PBS , rinsed with 0.1 M
glycine pH 2.5 for 5 minutes at room temperature to remove unlinked antibody, washed
once more in PBS, resuspended in PBS and stored at 4°C. To purify apoB fragments
from McArdle cell supernatant, these antibody-coated beads were incubated with the
supernatant samples overnight at 4°C with gentle rotation. The beads were then washed
once with PBS and then incubated for 5 minutes with 0.1 M glycine pH 2.5 and then
neutralized with 1 M Tris pH 8. The supernatant was collected and stored at 4°C.
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Preparation of Lipoproteins from Pooled Human Sera
Lipoproteins were isolated from whole pooled human sera using the OptiPrep reagent
(Sigma, St. Louis, MO) as described (Graham et al., 1996). To remove chylomicrons
from the samples, protease inhibitor-treated pooled human sera was placed in 14×89 mm
centrifuge tubes, covered with mineral oil, and centrifuged in an ultra centrifuge
(Beckman, Brea, CA) at 16°C at 100,000 × g for 30 minutes using a TH-641 swinging
bucket rotor. Following centrifugation, the mineral oil and white chylomicron layer were
removed and discarded and the chylomicron-free serum was combined into one conical
tube, mixed 4 parts serum to 1 part OptiPrep. Mixture was divided evenly into Optiseal
centrifuge tubes (Beckman, Brea, CA), with 3-4 mls solution in each and then covered
with a layer of Hepes-buffered saline solution (0.85% w/v NaCl, 10 mM Hepes-NaOH,
pH 7.4) on top to fill the tube up into the neck and tubes were sealed with the black plugs
included in the package. Tubes were place in balanced positions in a NVT 90 rotor and
secured with brass threaded caps and then centrifuged at 350,000 × g for 3 hours at 16°C.
Following centrifugation, the tubes were carefully removed and the top transparent layer
of the gradient containing VLDL was removed with a 5cc syringe fitted with an 18 gauge
needle; the yellow layer containing LDL was removed in a similar fashion. Fractions
were immediately dialyzed against sterile PBS in Slide-A-Lyzer dialysis cassettes
(Pierce, Rockford, IL) to remove the OptiPrep solution. ApoB protein concentrations of
the lipoprotein preps were determined by a human apoB ELISA (Cayman Chemical, Ann
Arbor, MI or Alerchek, Portland, ME).
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Preparation of AIP-Enriched Supernatant
Bacteria-produced AIP was prepared and concentrated by first growing an overnight
culture of agr2 strain 502A or agr3 strain MW2 in 15 ml of TSB in a 50 ml Falcon tube
at 37°C with 200 rpm shaking. The culture was then centrifuged at 4°C at 3000 rpm for 4
minutes, the supernatant was filtered through a 0.22 μm filter, and stored on ice.
Centricon YM-10 concentrator tubes (Millipore, Billerica, MA) were rinsed with
deionized water according to the manufacturer’s instructions by centrifuging in a Sorvall
RC2-B centrifuge with fixed angel rotor SS-34 at 1000 × g for 30 minutes. Supernatant
samples were then loaded onto the centricon tubes and centrifuged at 5000 × g for 1-1.5
hours. The resulting filtrate was aliquoted and stored at -80°C.

Mice
The appropriate institutional committees approved all experiments involving animals.
C57BL/6 mice (≈ 10 wk, ≈ 22-28 g) from Charles Rivers (Wilmington, MA), NADPH
oxidase knock-out on the C57BL/6 background (gp91phox-/-) (Pollock et al., 1995), B6 x
129, and PCSK9 knock-out (Pcsk9-/-) (Rashid et al., 2005) on the B6 x 129 background
all from Jackson Laboratory (Bar Harbor, ME) were gender- and age-matched. Mice
receiving 4APP treatment were injected i.p. 48 hours and 24 hours prior to infection with
100 µl of 5 mg/ml 4APP prepared by dissolving in 1 M HCl at 100 mg/ml and diluted to
5 mg/ml in 0.025 M phosphate buffer (pH 8). The solution was adjusted to pH 4 with
7.5% NaHCO3 immediately before injection. Total cholesterol levels were determined
using a kit and standard (Thermo Electron, Louisville, CO) following the manufacturer's
instructions. Wild-type levels were 113 ± 2.5 mg/dl, 4APP treatment reduced levels to
56.5 ± 1.9 mg/dl, and PCSK9 deficiency reduced levels to 84.3 ± 13 mg/dl.

35

Air Pouch Infection Model
Subcutaneous air pouches were created seven days before infection by injection of 5cc air
on the backs of healthy mice using a 5cc syringe and a 27 ½ gauge needle. Four days
prior to infection, the pouches were re-inflated with 2.5cc air. On the day of infection,
early exponential phase bacteria at the dose indicated in the figure legends were injected
directly into the pouch and mice were weighed, as previously described (Rothfork et al.,
2003; Rothfork et al., 2004). Twenty-five to 28 hours after infection, the mice were
weighed and scored for morbidity by the following scale: Appearance: 0-4; natural
behavior: 0-3; hydration status (skin pinch test): 0-3; provoked behavior: 0-4. The
morbidity score is the sum of the scores in the 4 categories with a maximum of 14 at
which point the mice were considered moribund. The animals were then euthanized by
isoflurane inhalation and the following samples were collected: blood, pouch lavage,
pouch tissue, and spleen. Blood was collected using a 19 gauge needle and a 1 cc syringe
to withdraw it from the aorta immediately after euthanasia; blood was placed in sterile
glass tubes and placed on ice for 2 hours. After clotting, the blood was centrifuged at
maximal speed at 4°C for 10 minutes and then sera was collected and stored at 4°C. The
pouch tissue was carefully exposed and rinsed with 5 ml 1X Hanks Balanced Salt
Solution containing 0.2% HSA; this lavage fluid was collected with a 10cc syringe and
18 gauge needle and transferred to a tube and stored on ice. Basolateral pouch tissue was
surgically removed and fixed in 3% paraformaldehye containing 0.1 mM CaCl2 and 0.1
mM MgCl in PBS for 3 to 4 hours on ice. Spleens were removed and placed in 1 ml of
HBSS/HSA in a bead beating tube containg several sterile 2.3 mm beads (Biospec,
Bartlesville, OK) and stored on ice. Lavage and spleen samples were processed for
bacterial CFU by homogenizing the spleens in a bead beater, diluting all samples 1:10 in
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1 ml 1X PBS/0.1%Triton, sonicating the sample, then plating serial dilutions on blood
agar, all as described (Rothfork et al., 2004). Cytokine levels in the filtered lavage fluid
were determined using a MIP-2 ELISA kit (R&D Systems, Minneapolis, MN).

Tissue Invasion Assay
After pouch tissues were fixed in 3% Paraformaldehyde for 3-4 hours they were rinsed in
PBS and were stored overnight in 25% sucrose in PBS, oriented and embedded in OCT
(Sakura Finetek, Torrance, CA) in cryomolds, frozen in liquid nitrogen, and stored at 80°C. Cryosections (10 µm) were cut onto slides and fixed and permeabilized with
acetone at -20°C for 5 minutes, rehydrated with PBS, blocked for endogenous biotin with
a streptavidin-biotin blocking kit (Vector Labs, Burlingame, CA), and blocked with 5%
normal rabbit serum in PBS containing 0.1% Tween and 1% BSA for 2 hr at 4°C. The
blocked sections were stained with 2µg/ml mouse IgG3 anti-S. aureus (GeneTex Inc, San
Antonio, Tx) labeled with biotin (FluoReporter Mini¬Biotin-XX, Molecular Probes,
Eugene, Or) for 1 hour at 4°C, rinsed and incubated with 0.5 µg/ml streptavidinrhodamine (Jackson ImmunoResearch, West Grove, PA) for 30 min at 4°C, rinsed, and
cover-slipped with ProLong Gold antifade reagent (Molecular Probes, Eugene OR).
Uninfected pouch tissue stained as above served as the negative control. Images were
acquired on a Zeiss LSM 510 confocal microscope. Bacterial density as a measure of in
vivo biofilm formation in the epidermis and tissue invasion into the dermis was quantified
from LSM images using Slidebook software (Intelligent Imaging Innovations, Denver,
CO). Regions of interest were selected using histiologic criteria for the epidermis (~first
100 µm) or dermis (~200-300 µm) and the total area and the portion of that area stained
for S. aureus quantified in microns2. Values are displayed as % of epidermis or dermis
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stained from a minimum of 19 sections for each experimental condition. Total bacteria
were determined by adding green, yellow and red fluorescence for the relevant sections
and quorum-sensing bacteria determined by adding green and yellow fluorescence for the
relevant sections.

Statistical Evaluation
Data are displayed as the mean ± SEM. In vitro data were analyzed by the Student’s t test
and the in vivo results by the Mann-Whitney U test for nonparametrics using StatView
for Macintosh or GraphPad Prism 4.0.
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CHAPTER 3
APOLIPOPROTEIN B IS AN INNATE BARRIER AGAINST
INVASIVE STAPHYLOCOCCUS AUREUS INFECTION
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Summary

Staphylococcus aureus is both a colonizer of humans and a cause of severe
invasive infections. Although the genetic basis for phenotype switching from colonizing
to invasive has received significant study, knowledge of host factors that antagonize the
switch is limited. We show that VLDL and LDL lipoproteins interfere with this switch by
antagonizing the S. aureus agr quorum-sensing system that upregulates genes required
for invasive infection. The mechanism of antagonism entails binding of the major
structural protein of these lipoproteins, apolipoprotein B, to an S. aureus autoinducing
pheromone, preventing attachment of this pheromone to the bacteria and subsequent
signaling through its receptor, AgrC. Mice deficient in plasma apolipoprotein B, either
genetically or pharmacologically, are more susceptible to invasive agr+ bacterial
infection, but not to infection with an agr deletion mutant. Therefore, apolipoprotein B at
homeostatic levels in blood is an essential innate defense effector against invasive S.
aureus infection.

Introduction

The host response to bacteria that both colonize their hosts and cause invasive,
lethal infection is complex and requires selective host defense effectors that limit invasive
infection while tolerating colonization at epithelial surfaces. Staphylococcus aureus
colonizes 20%–30% of the population persistently and another ~50% – ~60% transiently,
and, while the number of invasive infections is increasing, especially those caused by
methicillin-resistant bacteria (MRSA)-like strains of the USA300 PFGE type (Klevens et
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al., 2007), they still reflect a small percentage of colonized individuals. This suggests that
the majority of normal human hosts, even if colonized, have intact barriers to invasive
infection. Moreover, it suggests that failures in these barriers may increase the
susceptibility to invasive infection. Therefore, we postulated that specific elements of
acute inflammation are likely to discriminate between these two outcomes of S. aureushost interaction.
Virulence factor expression by S. aureus is regulated by a complex set of signals
that are integrated to induce transcription of genes required for survival within distinct
niches in response to sensing the host environment (Cheung et al., 2004; Torres et al.,
2007; Yarwood et al., 2002). agr is a four-gene operon present in the majority of S.
aureus clinical isolates that controls, in part, a change in phenotype from adhesive and
colonizing to tissue damaging and invasive (George and Muir, 2007). It encodes a
quorum-sensing system driven from the transcription of two promoters, P2 and P3; one
codes for synthesis and secretion of an autoinducing cyclic thiolactone peptide (AIP) and
a two-component regulatory pathway, and the other generates in response to AIP a
regulatory RNA transcript, RNAIII, that is the effector of the operon. Four different AIPs
are produced by S. aureus types that differ in amino acid composition and length but
retain the thiolactone structure (George and Muir, 2007) with type 1 AIP predominating
in clinical isolates. After RNAIII is produced, it downregulates expression of surface
adhesins while upregulating expression of secreted toxins, proteases, lipase, and
metabolic pathways (George and Muir, 2007). We postulated that innate immunity and,
specifically, elements of acute inflammation would regulate this phenotypic change and
thus contribute to maintaining the host-pathogen balance toward a noninvasive outcome.
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During acute inflammation, increases in vascular permeability result in plasma leakage
into the injured tissue (Bucci et al., 2005). Because AIP interaction with its receptor,
AgrC, involves, in part, recognition of the thiolactone ring by a hydrophobic pocket
within the receptor (Wright et al., 2004; George and Muir, 2007; Jensen et al., 2008), we
hypothesized that lipoproteins secreted by the liver and present in plasma that
extravasates to acutely infected tissue would antagonize AIP signaling through AgrC.
Here, we show that apolipoprotein B, the major structural protein of very low-density
lipoproteins (VLDL) and low-density lipoproteins (LDL), sequesters AIP1 and thus
inhibits agr signaling and limits invasive infection caused by both laboratory strains and
MRSA USA 300 isolates.

Results

Serum Low-Density Lipoproteins Antagonize Pheromone AIP1 Signaling
We hypothesized that constituents of plasma, specifically lipoproteins, could
provide a check against quorum-sensing-dependent virulence at sites of S. aureus
infection by interfering with the interaction of AIP with an essential hydrophobic pocket
within its cognate receptor AgrC (Wright et al., 2004; Jensen et al., 2008). Using a
reporter strain where activation of the agr P3 promoter drives expression of GFP
(Rothfork et al., 2004), synthetic AIP1 (100 nM) induced activation of the P3 promoter
optimally at 3 hr, and inclusion of dilutions of pooled human serum (PHS), as compared
to lipoprotein-deficient pooled human serum (LPDS), inhibited its function (Figure 1A),
indicating that serum lipoproteins can antagonize AIP1 signaling without affecting
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bacterial growth (CFU) (Figure 1A, inset). Inclusion of mouse, chicken, rabbit, or bovine
sera also inhibited activation (data not shown). Culture of the bacteria in 10% PHS also
inhibited spontaneous P3 promoter activation during longer culture times as compared to
10% LPDS without affecting bacterial growth, indicating that serum lipoproteins can
inhibit endogenous AIP function (Figure S1A, Appendix).
Purified human VLDL and LDL particles, as compared to high-density
lipoproteins (HDL) at equivalent cholesterol concentrations (0.4 mM), significantly
antagonized AIP1-induced P3 activation (Figure 1B) also with no effect on bacterial CFU
(data not shown). Moreover, inclusion of VLDL significantly inhibited AIP1-induced
RNAIII transcript production relative to 16S RNA as measured by qRT-PCR in the
USA300 clinical isolate UAMS1378 (Figure 1C). These data indicate that the lowest
density lipoproteins secreted by the liver into blood significantly and specifically
antagonize AIP1-dependent signaling in both laboratory strains and clinical isolates
associated with invasive infections.
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Figure 1. Serum Lipoproteins Antagonize agr Signaling
(A) agr:P3 promoter activation by 100 nM AIP 1 is inhibited in S. aureus (ALC 1743
with agr:P3-gfp, 2×107/ml) during 3 hr of culture with either broth or the indicated
dilutions of pooled human serum (PHS) as compared to lipoprotein deﬁcient sera
(LPDS). Magnitude of promoter activation was measured as ﬂuorescence induction
(mean channel of ﬂuorescence [MCF]). (Inset) Log CFU indicated that bacterial growth
was equivalent under both conditions. Data are represented as the mean ± SEM; n = 3
performed in duplicate.
(B) Effect of VLDL, LDL, or HDL at equivalent cholesterol concentration (0.4 mM) on
100 nM AIP1-induced agr:P3 activation during 3 hr of culture of ALC1743. Data are
represented as the mean ± SEM; n = 3 performed in duplicate.
(C) Relative quantiﬁcation of RNA III transcript to 16 s RNA produced by USA300
clinical isolate UAMS 1378 cultured at 2×107/ml with 100 nM AIP1 with or without 2
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mg/ml VLDL for 1 hr. Data are represented as the mean ± SEM; n = 4 performed in
triplicate.
(D) Dose-dependent inhibition of AIP1-induced agr:P3 activation by puriﬁed
apolipoprotein B, but not other serum lipoproteins. Concentrations tested: apoB, 2–8
μg/ml (4–16 nM); apoA-I, 4–8 μg/ml (143–288 nM); apoC-1, 4–8 μg/ml (0.61–1.2 mM);
and apoE, 4–8 μg/ml (117–234 nM).
(E) Goat IgG anti-apoB (5 μg/ml) versus control goat IgG reversed VLDL (5 μg/ml) and
puriﬁed apoB (5 μg/ml) inhibition of AIP1-induced agr:P3 activation in ALC1743. Data
are represented as the mean ± SEM; n = 3 performed in duplicate.
(F) mAB C1.4 IgG1 anti-apoB (5 μg/ml) versus control mouse IgG1 reversed VLDL (5
μg/ml) inhibition of 100 nM AIP1-induced relative RNA III transcript produced by
USA300 clinical isolate LAC cultured at 2×107/ml for 1 hr. Data are represented as the
mean ± SEM; n = 3 performed in duplicate.
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Apolipoprotein B Is Sufficient and Necessary to Antagonize AIP1 Signaling and
Secretion of Virulence Factors Required for Invasive Infection
Serum lipoproteins are complex particles composed of a neutral core containing
triglycerides and cholesterol esters covered by an amphipathic monolayer of
phospholipids and unesterified cholesterol. The protein, apo, components bind to the
surface of the particles and are either restricted to particular lipoproteins or freely
exchangeable across lipoprotein categories (Olofsson and Boren, 2005). We asked
whether the major structural nonexchangeable apo protein, apolipoprotein B, of VLDL
and LDL was able to inhibit AIP1-induced agr P3 promoter activation. ApoB inhibited in
a dose-dependent fashion at concentrations (8 μg/ml) less than normal serum values (~80
μg/ml) (Figure 1D) with no effect on bacterial CFU (data not shown). Other
apolipoproteins, apoA-1, apoC-1, and apoE, had no effect, indicating that AIP
antagonism is not a general property of lipid-binding proteins (Figure 1E). Treatment of
either VLDL or apoB with antibody against apoB, but not control IgG, reversed the
ability of both to inhibit AIP1-induced P3 activation (Figure 1E), indicating that any
associated lipids were not sufficient for antagonism and that antigenic epitopes of apoB
were essential. Moreover, VLDL inhibition of AIP1-induced RNAIII transcript
production in the USA300 strain LAC (also AIP1) was reversed by a monoclonal
antibody against an epitope in the amino terminal domain of apoB (mAb C1.4), but not
by an isotype control antibody (Figure 1F). Additionally, treatment of PHS with mAb
C1.4 versus an isotype control increased spontaneous P3 promoter activation in
ALC1743 and RNAIII transcript production in LAC during culture in the presence of
10% PHS (Figures S1B and S1C). Consistent with these data indicating apoB in the
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control of agr:P3 promoter activation, liposomes composed of various phospholipids and
cholesterol had no effect on AIP signaling (Figure S2A). Inclusion of the triglyceride
tributyrin partially reduced AIP signaling (Figure S2B), but it required concentrations
approximately five times higher than normally observed in serum. These data
demonstrate that apolipoprotein B is both sufficient and necessary for inhibition of AIP1
signaling in both laboratory strains and important clinical isolates.
Activation of agr contributes to the regulation of at least 70 genes, including 23
known virulence actors like α hemolysin and lipase. We determined the effect of VLDL
and purified apoB on α hemolysin (hla) promoter activation and secretion of α hemolysin
and lipase by multiple laboratory strains and clinical isolates, including MRSA isolates of
the USA 300 and 400 PFGE types that currently contribute to invasive human infection
(Klevens et al., 2007). Apolipoprotein B inhibited AIP1-induced hla promoter activation
(Figure S3A) and both AIP1-induced (Figure S3B) and spontaneous (Figure S3C)
secretion of α hemolysin by both a laboratory strain (SH1000) and multiple USA 300
isolates (USA 300 3757, UAMS 1378, and LAC). In addition, apoB and VLDL inhibited
AIP1-induced lipase secretion in all strains tested, including USA300 isolates (Figures
S3D and S3E). Moreover, apoB inhibited type 3 AIP signaling in a USA 400 strain,
suggesting that apolipoprotein B inhibition may not be limited to the type I peptide
(Figure S3B).
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Apolipoprotein B and Its Associated Lipid Particles Antagonize agr Signaling by
Inhibiting AIP1 Binding to Bacteria and Sequestering It for Uptake by
Macrophages
ApoB-containing lipoproteins could antagonize activation of the agr P3 promoter
either by blocking AIP1 binding to the bacteria or by inhibiting signaling consequent to
AIP1 binding. To determine whether apoB could block recognition of AIP1 by AgrC, we
evaluated binding of AIP1 synthesized with an FITC tag in the amino terminus to wildtype bacteria. Specific FITC-AIP1 binding was inhibited by ~50% by an equal
concentration of soluble native AIP1, indicating that FITC-AIP1 and native AIP1
compete equally for binding (Figure 2A). While both VLDL and purified apoB inhibited
FITC-AIP1 binding to both RN6390 and the clinical USA300 isolate, LAC (Figures 2A
and 2C), apoA-1 did not. Neither VLDL nor apoB inhibited binding of FITC-labeled IgG
to the bacteria, indicating that lipoprotein-mediated inhibition was specific to AIP and not
the FITC tag (Figure 2B). These data indicate that apoB-containing lipoproteins
antagonize agr signaling by blocking AIP1 binding.
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Figure 2. Apolipoprotein B and Its Associated Lipid Particles Inhibit AIP Binding to
S. aureus and Interact with AIP by Surface Plasmon Resonance
(A) S. aureus (RN 6390, 2×107/ml) was incubated with 1 mM FITC-AIP1 alone (vehicle
control) or in combination with potential inhibitors including 1 mM native AIP1, VLDL
(2 μg/ml), apoB (8 μg/ml), or apoA-1 (8 μg/ml) at 37°C for 3 hr. Speciﬁc binding was
measured by ﬂow cytometry. Data are represented as the mean ± SEM; n = 4.
(B) One micromolar FITC-IgG binding to S. aureus RN6390 was not inhibited by VLDL
or apoB. Data are represented as the mean ± SEM; n = 3.
(C) S. aureus (USA300 LAC, 2×107/ml) was incubated with 1 mM FITC-AIP1 in vehicle
control or in combination with VLDL (2 μg/ml) or apoB (8 μg/ml) at 37°C for 3 hr.
Speciﬁc binding was measured by ﬂow cytometry. Data are represented as the mean ±
SEM; n = 2 performed in duplicate.
(D) Biacore X100 analysis in resonance units (RU) of the interaction of 10 nM apoB,
apoC1, or apoA1 with either cyclic biotin-AIP1 or linear biotin-AIP1 immobilized on
streptavidin chips after 60 s of contact time followed by 60 s of dissociation time at a
ﬂow rate of 10 μl/min. Data are represented as mean ± SEM; n = 3–5.
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ApoB-containing lipoproteins could inhibit AIP1 binding either by occupying its binding
site in its cognate receptor or by sequestering AIP1 away from the bacteria. Unlike LDL
binding to Group A Streptococci (Han et al., 2006), we did not detect direct binding of
LDL to the S. aureus strains we studied under the conditions we examined (data not
shown). We used surface plasmon resonance (SPR) to compare direct binding of purified
apoB (10 nM) to either native AIP1 or linear AIP1 immobilized at equivalent
concentrations via a biotin at the amino terminus to a streptavidin-coated chip (Figure
2D). This binding was dose dependent (Figure S4A) and specific to apoB as equal molar
concentrations of apoC1 or apoA1 did not result in detectable binding as measured as
resonance units (Figure 2D). Injection of apoB over biologically inactive linear AIP1 did
not result in detectable binding even though equivalent amounts of the cyclic and linear
forms of AIP1 were bound to the chips (Figure 2D), indicating that an intact thiolactone
ring is required for interaction. Therefore, we determined whether other native AIPs and
AIPs modified to limit their biologic activity while retaining the thiolactone ring could
compete against immobilized AIP1 to prevent apoB binding. As predicted, soluble native
AIP1, but not linear AIP1, prevented apoB binding (Figure S4B). Native AIP2 and AIP4
were equivalent if not better than soluble native AIP1 and caused significant (p < 0.001)
inhibition of apoB binding to immobilized AIP1 (Figure S4B). Interestingly, AIP1 treated
with oxidants to create a methionine sulfoxide variant that lacks biologic activity
(Rothfork et al., 2004) and AIP3 synthesized with a tyrosine in the amino terminus that is
nonfunctional (Otto et al., 1998) prevented apoB binding to immobilized AIP1 (Figure
S4B), indicating that chemical modifications that result in loss of function but retain the
thiolactone ring permit interaction with apoB. A control cyclic peptide made by disulfide
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crosslinking had no effect (Figure S4B). In addition, apoB bound to immobilized AIP1
could be removed by washing with 0.5% SDS and the chip reused to demonstrate new
apoB binding, indicating that the interaction of apoB with AIP1 retained the native
conformation of AIP1 required for apoB recognition. This suggests that the interaction of
the two is reversible. These data indicate that apoB-containing lipoproteins antagonize
agr signaling by binding AIP through recognition of the thiolactone ring and preventing
AIP ligation of the AgrC receptor.
Because macrophages express scavenger receptors that bind apoB-containing
LDL modified either by oxidation or acetylation (Moore and Freeman, 2006), we
postulated that lipoprotein sequestering of AIP1 could contribute to host defense by
facilitating uptake and destruction of AIP1 by macrophages. LDL modified by
acetylation was equivalent to native lipoproteins in antagonizing AIP1 signaling, and the
inhibition was reversed by an mAb to an amino-terminal epitope in apoB, but not by an
mAb of the same isotype against a carboxy-terminal epitope, indicating that chemical
modification of LDL does not affect apoB antagonism of AIP1 (Figure 3A). To exclude
the possibility of a direct inhibitory effect of AcLDL on the bacteria, we incubated
bacteria with AIP1 and AcLDL for 3 hr, washed, and then incubated with either broth or
AIP1. These bacteria were fully able to demonstrate spontaneous activation of the agr:P3
promoter as well as respond to AIP (Figure 3B). To examine scavenger receptor uptake
of AIP1, murine RAW264 macrophages were incubated on ice with acetylated LDL with
a red fluorescent label (DiIAc- LDL) and then with FITC-AIP1. After increasing the
temperature to 37°C, the percentage of colocalization of the red and green fluorescence
was evaluated by confocal microscopy (Figure 3C). At 10 min, ~60% of the FITC-AIP1
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colocalized with Ac-LDL (Figure 3D). Controls included using unlabeled Ac-LDL that
demonstrated only green fluorescence, using DiI-Ac-LDL without FITC-AIP1 to
demonstrate only red fluorescence, and using FITC avidin to demonstrate that the
colocalization was specific to AIP1 and not to the FITC tag. To demonstrate that this
colocalization was dependent on apoB, an mAb that reversed apoB inhibition of AIP1
signaling (mAb C1.4, Figure 3A) significantly inhibited colocalization of FITC-AIP1
with AcLDL (Figure 3D). Complexes of AcLDL and FITC-AIP1 that were dialyzed prior
to addition to the cells demonstrated equivalent levels of colocalization (Figure 3D).
Similar results were obtained with primary murine bone marrow macrophages (data not
shown). These data demonstrate that modified LDL can specifically bind and sequester
AIP1 for uptake and destruction by macrophages present at the site of infection.
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Figure 3. Interaction of AIP with Modiﬁed LDL and Uptake by Macrophage
Scavenger Receptors
(A) LDL modiﬁed by acetylation (5 μg/ml) inhibits AIP1-induced agr:P3 promoter
activation, and the inhibition is reversed by an mAb to an N-terminal epitope of apoB
(mAb C1.4) (5 μg/ml), but not by an mAb against a C-terminal epitope (mAb 4C11) (5
μg/ml). Data are represented as the mean ± SEM; n = 3 performed in duplicate.
(B) Reversibility of AIP1-induced agr:P3 promoter activation inhibited by modiﬁed
LDL. Reporter bacteria incubated with 50 nM AIP1 and 5 μg/ml AcLDL for 3 hr ﬁrst and
then washed and incubated subsequently with either broth or 500 nM AIP1 demonstrated
both spontaneous and AIP1-induced agr:P3 promoter activation. Data are represented as
the mean ± SEM; n = 2 performed in duplicate.
(C) RAW264 murine macrophages were incubated ﬁrst with mixtures of ﬂuorescently
labeled and unlabeled AcLDL on ice and then with FITC-AIP1 for 10 or 30 min at 37° C.
Fixed cells were imaged by confocal microscopy. (First row) RAW cells incubated with
unlabeled AcLDL (10 μg/ml) and then with FITC-AIP1 (green ﬂuorophore, 1 mM).
Confocal images show no bleed through to the red channel. (Second row) RAW cells
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incubated with DiI-AcLDL (red ﬂuorophore, 1 μg/ml) and unlabeled AcLDL (9 μg/ml).
Confocal images show no bleed through to the green channel. (Third row) RAW cells
incubated with DiI-AcLDL (1 μg/ml) and unlabeled AcLDL (9 μg/ml) and then FITCAIP1 (1 mM). Images show colocalization of LDL and AIP. (Fourth row) RAW cells
incubated with DiI-AcLDL (1 μg/ml) and unlabeled AcLDL (9 μg/ml) and then FITCavidin (1 mM). The FITC tag does not colocalize with Ac-LDL.
(D) Percent colocalization of FITC-AIP1 with AcLDL determined at both early (mean ±
SEM; n = 38 cells) and later time points (mean ± SEM; n = 30 cells) using Slidebook as
described in Experimental Procedures. As controls, AcLDL was treated with mAb antiapoB (clone C1.4) (5 μg/ml) before interacting with FITC-AIP1, and the percent
colocalization (mean ± SEM; n = 50 cells) was signiﬁcantly reduced (p < 0.001). Also,
dialyzing the AcLDL/FITC-AIP1 complex prior to incubation with the macrophages
resulted in equivalent colocation (mean ± SEM; n = 36 cells).
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Mice with Genetically Low Levels of Plasma Apolipoprotein B Are More
Susceptible to agr+ versus Δagr S. aureus Infection
Synthesis of apolipoprotein B by hepatocytes initiates assembly of VLDL
particles that after secretion into blood are metabolized into LDL particles that are
removed for degradation by the LDL receptor. The absolute blood level of apoB is
determined by both liver VLDL secretion and the uptake and degradation of apoBcontaining particles by the LDL receptor (Shelness and Sellers, 2001). If apolipoprotein
B is essential for defense against quorum-sensing-dependent invasive infection, then
mice with low blood levels of apoB should be more susceptible to agr+ infection, but not
infection with an agr deletion mutant. To test this, we used an air pouch model of
infection to compare the responses of wild-type mice and mice with diminished blood
levels of apoB due to overexpression of the LDL receptor as a consequence of genetic
deletion of PCSK9, a subtilisin family proprotein convertase that downregulates LDL
receptor expression (Horton et al., 2007). These mice are viable, develop normally, and
are otherwise healthy (Rashid et al., 2005), unlike apoB knockout mice that have multiple
development problems and early embryonic lethality (Farese et al., 1995). Pouches
generated by the subcutaneous injection of air become lined with epithelium over 6 days
and have been used to study in vivo bacterial bioﬁlm formation (Yoshikawa et al., 2004)
(Figure 1E), and we have shown that agr contributes to invasive infection in this model in
a dose-dependent manner (Rothfork et al., 2003, 2004). Infection of Pcsk9-/- mice (black
bars) with early exponential phase (i.e., nonﬂuorescent) agr P3:gfp reporter bacteria at a
dose handled easily by wild-type mice (white bars) resulted in signiﬁcantly greater
morbidity, bacterial burden at the site of infection and spleen, agr P3 promoter activation
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by the bacteria at the site of infection, inﬂammatory cytokine (MIP-2) concentration at
the site of infection, and epidermal bioﬁlm formation and invasion into the dermis
(Figures 4A–4D). In contrast, infection with an equivalent CFU of an isogenic agr
deletion mutant resulted in no signiﬁcant differences between wild-type and Pcsk9
knockout mice (Figures 4A, 4B, and 4D). Importantly, Pcsk9 deﬁciency at this challenge
dose revealed signiﬁcant differences in morbidity, bacterial burden, and MIP-2
concentration between agr+ and agr- infected mice (black bars, Figures 4A, 4B, and 4D),
demonstrating its requirement to control contributions of agr to pathogenesis.
Microscopic evaluation of the pouch tissue from either strain of mice infected with the
agr deletion mutant and stained with anti-S. aureus linked to a red ﬂuorophore revealed
minimal numbers of detectable bacteria (data not shown). In contrast, confocal
microscopy of pouch tissue from the Pcsk9-/- mice infected with either early (Figure 4F,
right panel) or midexponential phase (Figure 4G right panel) agr+(ALC1743) bacteria, as
compared to wild-type mice (Figures 4F and 4G, left panels), had signiﬁcantly greater
bacterial density in the epidermis (measure of bioﬁlm formation) and signiﬁcantly greater
numbers of GFP-expressing bacteria (either green or yellow), indicating that they had
undergone quorum sensing (quantiﬁcation shown in Figures 4F and 4G graphs).
Moreover, the bacterial density, the magnitude of in vivo quorum sensing, and invasion
beyond the epidermis into the dermis and underlying muscle correlated with the
morbidity score of the mice, and in all cases, these were signiﬁcantly greater for the
apoB-deﬁcient mice (Figures 4F and 4G, right panels and graph). These data indicate that
the reduction of apoB-containing lipoproteins in the plasma of otherwise healthy mice
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makes them signiﬁcantly more susceptible to quorum-sensing-dependent invasive
infection, but not to infection by nonquorum-sensing S. aureus.

VLDL and LDL Represent an Additional Barrier beyond the NADPH Phagocyte
Oxidase for Control of agr+ versus Δagr S. aureus Infection
The phagocyte NADPH oxidase (phox) plays multiple roles in host defense
against S. aureus infection (Quinn et al., 2006; Kobayashi et al., 2004). We previously
demonstrated that its contribution to oxidant inactivation of AIP1 signaling contributes,
in part, to control of quorum-sensing-dependent infection (Rothfork et al., 2004). To
determine that apoB-containing lipoproteins represent a separate and distinct barrier
against invasive quorum-sensing-dependent infection, we used pharmacologic treatment
to lower plasma apoB levels of mice genetically deﬁcient in phox (gp91phox-/-) (Pollock et
al., 1995). Phox-deﬁcient mice treated with a drug 4APP that inhibits low-density
lipoprotein secretion by the liver (Mounkes et al., 2001) were signiﬁcantly more
susceptible to MRSA USA300 LAC agr+ infection than vehicle control-treated mice.
They had signiﬁcantly greater morbidity, weight loss, and bacterial burden at the site of
infection and systemically (Figures 5A–5C). In contrast, 4APP treatment of these mice
did not increase susceptibility to infection with the agr deletion mutant (Figures 5A–5C).
Importantly, as with Pcsk9 deﬁciency, 4APP treatment revealed signiﬁcant differences in
morbidity, weight loss, and bacterial burden between agr+ and Δagr infected mice
(Figures 5A–5C). Microscopic evaluation of the pouch tissue stained with anti-S. aureus
(red ﬂuorescence) revealed signiﬁcantly greater bacterial density in the epidermis of
4APP-treated mice infected with agr+ bacteria (Figures 5D and 5E). In contrast, 4APP
treatment had no signiﬁcant effect on the pouch tissue of mice infected with the agr
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Figure 4. Effect of agr on S. aureus Infection of Apolipoprotein-Deﬁcient Pcsk9-/Mice as Compared to Wild-Type Mice
Air pouches generated on the backs of B6×129 wild-type or Pcsk9-/- mice (n = 8 for each
group) were infected with either 3.5×107 nonﬂuorescent early exponential phase S.
aureus agr:P3-gfp ALC 1743 (agr+) or 3.2×107 agr:P3-gfp ALC1753 (agr-). At 28 hr
postinfection, the following parameters were determined and represented as the mean ±
SEM:
(A) Morbidity was scored on a 0–14 point scale.
(B) Bacterial burden (Log CFU) of pouch lavage and spleen.
(C) Quantiﬁcation of agr:P3-gfp promoter activation by ﬂow cytometry of bacteria
isolated from the pouch lavage.
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(D) MIP-2, a murine inﬂammatory cytokine, was measured in the pouch lavage.
(E) H & E stain of the basal section of pouch tissue demonstrating bacteria at the surface
of the lumen, the epidermis and dermis with inﬁltrating leukocytes, and the skeletal
muscle.
(F) Representative pouch tissue from B6×129 mice (left panel) versus Pcsk9-/- mice (right
panel) infected with early exponential phase S. aureus (agr:P3-gfp ALC1743). Pouch
tissue was ﬁxed and sectioned, and sagittal sections were stained with anti-S. aureus
antibody (red ﬂuorophore). Quorum-sensing S. aureus were visible by production of GFP
in the pouch. Graph represents the relative density of both total and GFP+ bacteria in the
epidermis from at least 19 representative areas.
(G) Representative pouch tissue from B6×129 mice (left panel) versus Pcsk9-/- mice
(right panel) infected with midexponential phase S. aureus (agr:P3-gfp ALC1743) and
stained with anti-S. aureus (red ﬂuorophore) demonstrated signiﬁcantly more quorum
sensing, bioﬁlm formation, and invasion into the dermis at 28 hr postinfection in Pcsk9-/mice. Graph represents the relative density of both total and GFP+ bacteria in the
epidermis from at least 19 representative areas. *p < 0.02; **p < 0.005. L = lumen, D =
dermis, E = epidermis, and MS = morbidity score. Arrows indicate point of greatest
penetration by quorum-sensing bacteria. Scale bar, 50 μm.
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deletion mutant. Importantly, 4APP-treated mice infected with wild-type LAC had
signiﬁcantly increased density of bacteria that had invaded deep into the dermis and
muscle underlying the air pouch with bacteria surrounding the muscle ﬁbers (Figures 5F
and 5G). Equivalent results were obtained with the agr+ and agr- RN6390 strains (Figure
S5) and with the USA300 UAMS1378 strain and its agr deletion mutant (UAMS1540)
(Figure S6). These data indicate that secreted low-density lipoprotein represents an innate
barrier against quorum-sensing-dependent invasive S. aureus infection caused by agr
type 1 laboratory strains or MRSA clinical isolates associated with invasive skin
infections.

Discussion

Staphylococcus aureus, a colonizer of mucosal and epithelial surfaces and a pathogen
capable of invading beyond these barriers, uses a complex network to regulate gene
transcription essential for survival at these different sites. One mechanism by which the
innate immune system could provide defense against invasive infection is not just by
providing effectors that lead to bacterial killing but also by providing effectors that target
virulence systems that permit survival beyond the epithelial barrier. In this work, we
demonstrate that the major structural protein of VLDL and LDL, apolipoprotein B,
antagonizes the agr quorum-sensing operon and selectively limits invasive infection of
agr group 1 bacteria to epidermal spaces without any direct bactericidal effect.
Importantly, we were able to show a role for these lipoproteins in control of invasive
MRSA USA300 infections that are increasing in number and severity (Klevens et al.,
2007).

61

Figure 5. Effect of agr on USA300 (LAC) S. aureus Infection of NADPH Oxidase
Knockout (gp91 phox-/-) Mice Treated with 4APP to Inhibit Liver Secretion of
Lipoproteins
Mice were treated with 100 μl of 5 mg/ml 4APP or vehicle control (0.025 M phosphate
buffer) (n = 4 for each group) i.p. 48 and 24 hr prior to infection of air pouches with
either 2.5×107 CFU of USA300 LAC or LAC Δ agr. At 25 hr postinfection, the following
parameters were determined and the data represented as the mean ± SEM:
(A) Morbidity was scored on a 0–14 point scale.
(B) Weight loss in grams.
(C) Bacterial burden (Log CFU) in pouch lavage and spleen.
(D) Representative pouch tissue from control and 4APP-treated mice stained with anti-S.
aureus antibody (red ﬂuorophore), demonstrating bioﬁlm-like aggregates (arrowhead)
and increased numbers of bacteria in the epidermis in 4APP-treated mice infected with
wild-type LAC. Scale bar, 50 μm.
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These data extend our previous observation that reactive oxygen and nitrogen
intermediates generated by the phagocyte oxidase inactivate the type 1 autoinducing
pheromone of the agr operon (Rothfork et al., 2004), demonstrating that multiple
effectors of innate immunity provide defense by targeting virulence gene regulation by S.
aureus. However, in contrast to the current work, the phagocyte oxidase provides defense
by multiple mechanisms, including both intracellular and extracellular killing of this
pathogen (Ahluwalia et al., 2004; Fuchs et al., 2007; Quinn et al., 2006). Another
example of a mammalian defense effector that targets quorum-sensing signaling without
affecting bacterial viability is the paraoxonase family of lactonases that inactivate the
acyl homoserine lactone pheromones of Pseudomonas aeruginosa (Ozer et al., 2005;
Yang et al., 2005).
Apolipoprotein B is a large (4536 amino acids) amphipathic lipid-binding protein
with a pentapartite structure composed of a globular amino terminus, two domains of β
pleated sheets, and two α-helical domains that span the entire surface of the lipoprotein
particle (Segrest et al., 2001; Olofsson and Boren, 2005). While it never exists in blood
independently of the associated lipid particle, our data indicate that this structural protein
is responsible for VLDL and LDL inhibition of AIP1 binding and signaling because (1)
the individual lipid constituents of the lipoprotein particles at normal serum concentration
did not inhibit AIP1 function, (2) antibody against apoB reversed VLDL, LDL, and
AcLDL inhibition, (3) apoB puriﬁed away from its associated lipid by ether extraction
and size chromatography was sufﬁcient for inhibition, and (4) apoB bound directly to
immobilized native AIP1, but not linear AIP1, by SPR. While direct binding of LDL via
apoB to prions (Safar et al., 2006) and group A streptococci (Han et al., 2006) has been
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demonstrated, whether this contributes to host defense and/or to virulence is unknown.
We did not detect direct binding of LDL to the strains we studied. Therefore, we believe
that the mechanism of antagonism involves sequestering of AIP1 by apoB within the
lipoprotein particle. While the domain or site involved is presently not known, a
monoclonal antibody to an epitope in the amino terminus reversed apoB interaction with
AIP1, suggesting that the amino-terminal domain that initiates lipoprotein assembly in
the liver may be involved. In addition, analysis of the SPR kinetic data revealed that
either a one-to-one or a two-site interaction model could explain our results. Therefore,
isolation of the domain or domains involved will be required for deﬁnitive data on the
afﬁnity of binding and the relevant stoichiometry. Moreover, because alterations in the
lipid composition of VLDL and LDL are known to alter the conformation of apoB (Wang
et al., 2000) and apoB within VLDL appeared more potent than puriﬁed apoB in our
assays, the conformation of apoB as modiﬁed by associated lipid may contribute to AIP
antagonism.
While the majority of our data were demonstrated with apoB interaction with
AIP1 that predominates in clinical isolates, incubation of AIP2 and AIP4 with apoB
prevented its binding to solid phase AIP1 and apoB inhibited AIP3-induced hemolysin
production, indicating that apoB may be involved in regulating quorum sensing in all four
S. aureus types. Because all four AIPs have different amino acid sequences but retain the
thiolactone ring (George and Muir, 2007) and apoB did not bind to linear solid phase
AIP1, we suspect that antagonism requires recognition of a thiolactone-dependent
conformation that is essential for binding to the cognate AgrC receptor (Wright et al.,
2004; Jensen et al., 2008). Once bound via apoB to the lipoprotein particle, AIP could be
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degraded following uptake by macrophage scavenger receptors (Moore and Freeman,
2006). Intriguingly, mice deﬁcient in one of these, CD 36, are more susceptible to S.
aureus infection (Hoebe et al., 2005; Stuart et al., 2005), and whether this involves
impaired control of quorum sensing is a point of speculation. Finally, because neat
lipoprotein-deﬁcient serum retained some ability to inhibit AIP1 signaling, other in vivo
antagonists of AIP function are likely to contribute to control of quorum sensing.
The agr operon is only one of many global regulators that act subsequent to
speciﬁc sensing to alter expression of various virulence factors by S. aureus (Cheung et
al., 2004; Torres et al., 2007). However, the majority of clinical isolates are agr+, and agr
deletion mutants are attenuated particularly in skin infection models (Rothfork et al.,
2003, 2004; Wright et al., 2005), suggesting that, even though it shares targets with other
regulators, it has a unique role in the pathogenesis of S. aureus infections. In our model,
Δagr bacteria are conﬁned to the ~100 μm of the epidermis at the base of the air pouch,
indicating that agr-mediated repression of adhesins that retain bacteria in the epidermis
and upregulation of tissue-degrading enzymes are required for bacterial invasion into the
dermis and possibly across the endothelium into the blood stream. In addition, our data
demonstrate that the NADPH oxidase of phagocytes and VLDL and LDL in plasma play
nonredundant roles in limiting AIP1-dependent activation of agr at this site. However,
this has not been conﬁrmed for all AIP types. In acute inﬂammation, leukocyte
emigration across the endothelium into injured tissue occurs early with subsequent
vascular leakage and plasma extravasation (Bucci et al., 2005) and, thus, would provide
temporal control of agr activation. Moreover, sites of acute infection can become rapidly
hypoxic (Peyssonnaux et al., 2005), which would limit oxidase control of AIP function,
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and extravasated lipoprotein-mediated inhibition would predominate. If this barrier fails,
the bacteria would gain access via the blood stream to virtually every tissue site. In the
vasculature, agr may have little if any role (Yarwood et al., 2002), and recent data
indicate that hemoglobin released from lysing erythrocytes or present within
reticuloendothelial tissues actively suppresses production of the agr effector, RNAIII
(Schlievert et al., 2007), possibly through the newly described heme sensor system
HssRS (Torres et al., 2007), leading to reduced toxin production and attenuation. This
could beneﬁt the bacterium by permitting re-expression of adhesins required for
attachment to endothelium to aid in escape from the neutrophil-rich blood stream into
other tissues. In the blood stream, quorum sensing would be limited to bacteria able to
escape antagonism or repression of agr either by clumping to prevent inactivation of the
AIP (Rothfork et al., 2003) or by internalization into cells. Thus, multiple cycles of agr
activation and repression regulated by both the pathogen and the host may occur during
pathogenesis of this infection.
Lipoprotein particle levels and their constituents are extensively altered by acute
inﬂammation and infection (Gabay and Kushner, 1999). In fact, hypocholesterolemia has
been consistently correlated with worse outcomes in critically ill patients (Gordon et al.,
2001; Gui et al., 1996; Marik, 2006; Windler et al., 1994) The molecular mechanisms
underlying this are poorly understood, but measurements of various lipid parameters in
patients with severe sepsis or septic shock indicate that apoB lipoprotein levels can be
very low (Kitchens et al., 2003;Vermont et al., 2005; van Leeuwen et al., 2003). Because
our data indicate that homeostatic levels of apoB-expressing lipoproteins are required to
provide adequate defense against quorum-sensing invasive S. aureus infections, clinical
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scenarios that result in extremely low apoB-containing lipoproteins may increase the risk
of invasive S. aureus infection, including MRSA infections. In this regard, no detailed
analyses of lipoprotein metabolism have been performed on patients with limited versus
invasive S. aureus infection. Moreover, expression of truncated variants (Shelness et al.,
2003) and/or known polymorphisms in apoB (Chiodini et al., 2003) may affect its ability
to antagonize agr signaling depending on the site or domain within apoB that binds AIP.
Therefore, variations in either the quality or amount of apoB in plasma may alter innate
defense against quorum sensing by this pathogen.
Our data do not address whether excess apoB-containing lipoproteins as would
occur in hyperlipidemia can prevent infection. In fact, high circulating levels of oxidized
LDL contribute to impaired Th1 immunity and increased susceptibility to experimental
infection with some pathogens (Shamshiev et al., 2007), suggesting, in conjunction with
the present work, that dyslipidemia alters multiple parameters required for host defense
(Marik, 2006). While the majority of work published to date on the role of lipoproteins in
host defense has focused on neutralization of lipopolysaccharide (Kitchens et al., 2003),
our work deﬁnes a previously unrecognized role of lipoproteins in interfering with
bacterial communication.
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Experimental Procedures
Reagents
Synthetic AIPs were generated as follows and stored in DMSO at -80°C: cyclic AIP1
(YSTC[→M]DFIM[→C]), FITC-AIP1, and biotin-AIP1 were synthesized by
Commonwealth Biotechnologies, Inc., Richmond, VA, using a described method (Otto et
al., 1998). Cyclic AIP 2 (GVNAC[→F]SSLF[→C]), AIP4 (YSTC[→M]YFIM[→C]),
and AIP3 antagonist (YINC[→L]DFLL[→C]) were generated as described (Otto et al.,
1998). A disulﬁde linked cyclic peptide, C(→C)LLRMKSAC(→C), was used as a
control. Linear AIP1 and biotin-AIP1 were generated by alkaline hydrolysis and
neutralization, and a methionine sulfoxide variant of AIP1 was produced by incubation
with hydrogen peroxide and myeloperoxidase as described (Rothfork et al., 2004). Both
were checked for loss of functional activity and structure by mass spectroscopy as
described (Rothfork et al., 2004). The following reagents and sera were obtained as
indicated: puriﬁed human VLDL, LDL, HDL, apoB, apoA1, apoC1, and apoE (US
Biological, Swampscott, MA); puriﬁed Ac-LDL, DiI-Ac-LDL, and DiI-LDL (Biomedical
Technologies Inc., Stoughton, MA); pooled human serum, lipoprotein-deﬁcient serum,
chicken serum, tributyrin, 4-aminopyrazolo-(3,4-D) pyrimide (4APP), and a liposome
preparation reagent containing cholesterol, phosphatidyl choline, and stearylamine
(Sigma-Aldrich, St. Louis, MO); cholesterol and phosphatidylcholine (Avanti Polar
Lipids); polyclonal goat IgG anti-human apolipoprotein B 100 (R&D Systems,
Minneapolis, MN); monoclonal murine IgG1 anti-human apoB C1.4 (Santa Cruz
Biotechnology, Santa Cruz, CA); and monoclonal murine IgG1 anti-human apoB 4C11
(Biodesign International, Saco, ME).
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Bacterial Strains and Culture
The bacterial strains used in this study were as follows: ALC 1743 (agr group 1 RN6390
containing reporter agr:P3-gfp), ALC 1740 (RN6390 containing reporter hla-gfp), ALC
1753 (RN6911 agr deletion mutant of RN6390 containing reporter agr:P3-gfp), RN6390,
SH1000 (σ B corrected RN6390), and ALC 1225 geh-(strain 8325-4 with geh deletion
mutant with reduced lipase secretion) (Kupferwasser et al., 2003; Rothfork et al., 2004).
USA300 strain UAMS1378 and its agr deletion mutant UAMS1540 were provided by
Dr. Mark Smeltzer (University of Arkansas), and USA300 strain LAC and its agr
deletion mutant were prepared as described (Wang et al., 2007). Clinical isolates of CAMRSA agr group 1 USA 300 (NM 300) and agr group 3 USA 400 (NM 400) were
provided by Dr. Steve Young, Department of Pathology, University of New Mexico, and
USA 300 strain FPR 3757 was provided by Dr. Francoise Perdreau-Remington, UCSF.
To generate synchronized early exponential phase, nonﬂuorescent bacteria, frozen stocks
were cultured either in Columbia broth or Trypticase soy broth (TSB) (Becton Dickinson,
Franklin Lakes, NJ) as described (Rothfork et al., 2003). CFU were determined after
washing and sonication to disrupt clumps by plating serial dilutions on blood agar
(Becton Dickinson, Franklin Lakes, NJ).

Bacterial Promoter Activation
Early exponential phase, nonﬂuorescent reporter bacteria (ALC1743 and ALC1740) (2 ×
107/ml) were incubated in 1 ml TSB in polystyrene tubes with shaking (200 rpm, 37°C)
for the indicated times with either broth or vehicle control, synthetic AIP1 (100 nM), or
AIP1 treated with antagonists including sera, lipoprotein particles, apo protein, or other
lipids. For inhibition of spontaneous activation of agr:P3, AlC1743 was incubated with
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90% TSB with either 10% PHS, 10% LPDS, 10% PHS preincubated on ice for 30 min
with 10 μg/ml murine IgG1, or 10% PHS preincubated on ice for 30 min with mAB C1.4
for the times indicated in the ﬁgure legend. After incubation, bacteria were washed by
centrifugation at 3000 rpm for 4 min at 4°C in PBS with 0.1% Triton X-100, sonicated,
cultured for CFU, and then ﬁxed with 1% paraformaldehyde containing 25 mM CaCl2
for analysis by ﬂow cytometry (FACSCalibur, Becton Dickinson, Franklin Lakes, NJ).
Promoter activation was demonstrated as ﬂuorescence induction and measured as the
mean channel ﬂuorescence (MCF) of GFP-positive bacteria.

Quantitative RT-PCR
Early exponential phase USA300 strains UAMS1378 or LAC (2 × 107/ml) were cultured
as above with either broth, 100 nM AIP1, or AIP1 with 2 μg/ml VLDL for 1 hr. For
strain LAC, the VLDL was preincubated with either IgG1 anti-apoB (mAb C1.4) or
isotype control (both 5 μg/ml) on ice for 30 min prior to addition to the assay. In addition,
LAC was incubated with either 10% PHS treated with murine IgG1 or with 10% PHS
treated with mAb C1.4 anti-apoB and cultured as indicated in the ﬁgure legends. RNAIII
was quantiﬁed relative to 16S RNA using a probe-based assay as described with minor
modiﬁcations (Sawires and Gresham, 2008) as detailed in Chapter 2.

Surface Plasmon Resonance
Surface plasmon resonance was performed with the Biacore X100 (Biacore Life
Sciences, GE Healthcare) to analyze the interaction of apoproteins with immobilized
AIP1. N-terminal biotinylated AIP1 in both the native and linear conformation were
immobilized on streptavidin sensor chips according to the manufacturer’s protocol. The
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details of the conditions of running the assays and their evaluation are given in Chapter 2
and the figure legends.
Additional experimental details of virulence factor assays, FITC-AIP1 binding to the
bacteria, macrophage colocalization experiments, and the air pouch model of infection
and its evaluation are given in Chapter 2.

Statistical Evaluation
Data are displayed as the mean ± SEM. In vitro data were analyzed by the Student’s t test
and the in vivo results by the Mann-Whitney U test for nonparametrics using StatView
for Macintosh.
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CHAPTER 4
APOLIPOPROTEIN B DIFFERENTIALLY PROTECTS AGAINST
INVASIVE STAPHYLOCOCCUS AUREUS INFECTION BASED ON
AGR TYPE
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Summary
Staphylococcus aureus is a colonizer of the human skin and mucosa that can also
cause severe invasive disease. The phenotypic switch from colonization to invasion is
mediated by bacterial pheromone peptide activation of the S. aureus agr quorum-sensing
system that upregulates virulence genes necessary for invasive infection. As an innate
host defense mechanism, apolipoprotein B binds to the bacterial quorum sensing peptides
and antagonizes virulence gene expression. Here we show preliminary data which
suggests that the effectiveness of apoB as a barrier to invasive infection is dependent on
the type of agr peptide made and secreted by the bacteria. Initial experiments suggested
that mice with pharmacologically lowered serum apoB are more susceptible to agr type
2, but not type 3 strains, compared to controls. This may explain why agr3 strains cause a
high incidence of bacteremic infections that are poorly controlled by the host.

Introduction
Host defense mechanisms against organisms that can both colonize and cause
infection must necessarily be multi-faceted and complex. Staphylococcus aureus is one
such organism: 20%-30% of humans are persistently colonized, while another 60%
experiences transient colonization. While primarily considered an opportunistic pathogen
causing infection in individuals with chronic medical conditions and at the extremes of
age, the emergence of community acquired methicillin resistant S. aureus (CA-MRSA)
infections in health individuals with no underlying health problems (Miller et al., 2005)
has focused interest on CA-MRSA infection as a major public health threat. In this
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regard, research from the Centers for Disease Control confirmed that in 2005 more deaths
occurred in the USA from MRSA infection than HIV infection and MRSA was
responsible for more cases of invasive bacterial infections than all other pathogens
combined (Klevens et al., 2007). Importantly, very little is known about host factors that
regulate susceptibility to CA-MRSA infection (Lowy, 2007)
Numerous innate mechanisms contribute to control S. aureus infection, including
neutrophil recruitment to the site of infection, oxidant-mediated killing, antibacterial
molecules and peptides, and neutralizing antibodies (Fournier and Philpott, 2005; Ganz et
al., 1985; Holtfreter et al., 2010). Previously, we identified serum apolipoprotein B
(apoB) found on low and very low density lipoproteins (LDL, VLDL) as an innate barrier
to S. aureus virulence gene expression and invasive infection (Peterson et al., 2008).
ApoB interacts with a bacterial quorum sensing signaling peptide (autoinducing peptide,
AIP) such that the peptide is sequestered away from its bacterial receptor AgrC. AIP is a
cyclic thiolactone peptide and its biologic function requires the cyclic form of the peptide
and the presence of carboxy terminal hydrophobic amino acids (Novick, 2003). ApoB
binds to the cyclic biologically active form of the peptide but not to the linear form. By
this mechanism, apoB inhibits a phenotypic switch in this pathogen preventing an
upregulation of virulence factors required for invasive infection. This switch is mediated
in part by a quorum sensing operon agr which contains two divergent promoters: the P2
promoter drives synthesis of AIP, its transporter AgrB, its receptor (AgrC), and the
response regulator protein AgrA; the P3 promoter responds to activated AgrA by driving
expression of a regulatory RNA, RNAIII, which induces gene expression of virulence
factors important for invasion and repression of colonizing factors (Novick, 2003). The
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P2 promoter is also activated by AgrA, thereby perpetuating an AIP-dependent
autoinducing loop. AgrA also directly activates the promoter for a cytolytic peptide, PSM
alpha, which is a known virulence factor in CA-MRSA strains and causes neutrophil lysis
at the site of infection (Wang et al., 2007).
S. aureus strains are divided into one of four agr types depending on the
sequence of the AIP produced and sequence variations in the cognate AgrC receptor. The
MRSA strains causing the majority of community-acquired disease, PFGE types USA300
and USA400, are agr types 1 and 3, respectively. Although the greater part of CA-MRSA
disease is attributed to the USA300 strain, those cases caused by an agr3 USA400 strain
often lead to severe persistent bacteremia (Tenover et al., 2006; Xiong et al., 2009).
USA100, which is found mostly in hospital-acquired cases, is an agr type 2 strain.
Whether apoB binds directly to all AIP types is unknown. Because bloodstream S. aureus
infections are predominantly caused by agr type 3 strains, we hypothesized that apoB is
primarily important for control of agr1 and agr2 infections and not for infections caused
by agr3 strains (Xiong et al., 2009).

Results
ApoB-containing Lipoproteins Bind to AIPs of Multiple agr Types
The overall structure of AIP across agr types of S. aureus is very similar, each
containing a thiolactone ring which is important for binding to the cognate bacterial
receptor AgrC (Figure 1A) (Jensen et al., 2008; Wright et al., 2004). However, key
differences among the peptides, such as peptide length and composition, distinguish them
one from another and from their receptors, such that a peptide from one agr type can
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inhibit receptor activation from another type (Ji et al., 1997). Based on our previous
observation that apoB binds cyclic but not linear AIP1 (Peterson et al., 2008), we
hypothesized that apoB and apoB-containing lipoproteins would also bind to AIP2 and
AIP3, since all AIPs share a hydrophobic cyclic structure. We used surface plasmon
resonance (SPR) to analyze binding of purified apoB, LDL, and VLDL to the different
AIPs (Figure 1B). AIP was N-terminally biotinylated to allow immobilization to a
streptavidin-coated chip and apoB, LDL and VLDL were used at equivalent apoB molar
concentrations as determined by ELISA (Cayman Chemical, Ann Arbor, MI or Alerchek,
Portland, ME). Binding between each of the analytes and AIPs was observed, with
binding to AIP2 resulting in the greatest response overall as measured by resonance units
(RU), with intermediate binding to AIP1 and the least binding to AIP3. These results
suggest that in this system the length of peptide correlated with the magnitude of binding.
To address this, we measured binding to modified AIP3 synthesized with an aminoterminal tyrosine (Y-AIP3). Addition of the N-terminal tyrosine residue to AIP3 resulted
in increased binding by the apoB-containing analytes to a level comparable to that bound
to AIP1 indicating that the length of the amino acid tail also contributes to recognition of
AIP by apoB. Interestingly, VLDL binding of each AIP type was greater than binding by
either LDL or apoB, between which resulting RU were comparable. This observation
suggests that the conformation of apoB within VLDL particles may enhance its
interaction with AIP. Alternatively, the lipids within VLDL may play a more direct role
in recognition of AIP. Differentiation of these possibilities will require further
investigation. These data demonstrate that apoB either as a purified protein or within a
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lipoprotein particle binds AIP2 > AIP1 = Y-AIP3 > AIP3, suggesting that apoB may have
the least control of agr type 3 infections.
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Figure 1. Structure and Binding of AIPs to apoB-containing Particles by Surface
Plasmon Resonance
(A) Peptide sequences of the signaling pheromone peptide AIP from agr groups 1, 2, and
3. A conserved central cysteine residue forms a thiolactone ring structure essential for
AIP signaling through the bacterial AgrC receptor.
(B) Biacore X100 analysis in resonance units (RU) of the interaction of 20 nM apoB,
LDL, or VLDL with biotin-AIP1, biotin-AIP2, biotin-AIP3, or biotin-Y-AIP3
immobilized on streptavidin chips after 60 s of contact time followed by 60 s of
dissociation time at a ﬂow rate of 10 μl/min. Data are represented as mean ± SEM; n = 24.
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Apolipoprotein B Inhibits AIP-induced Virulence Factor Production
Based on the results of apoB binding to all AIP types and our previous
demonstration of apoB antagonism of AIP1-mediated quorum sensing dependent
virulence (Peterson et al., 2008), we asked whether apoB-containing lipoproteins can
antagonize AIP2 and AIP3-mediated quorum sensing and virulence factor upregulation in
vitro. To address this, we used qRT-PCR to measure RNAIII expression in the agr2
strain 502A (Blair and Tull, 1969; Light et al., 1967) following exogenous stimulation
with bacterial-derived AIP2. Specifically, early-exponential phase 502A were grown for
2h at 37°C with and without AIP2 derived from concentrated overnight supernatant in the
presence or absence of VLDL or apoB at equimolar apoB concentrations. As shown in
Figure 2A, RNAIII expression was significantly inhibited by VLDL and, to a slightly
lesser extent, by apoB. We next examined the ability of apoB-containing lipoproteins to
antagonize production of a key virulence factor, the toxin alpha hemolysin. Alpha
hemolysin is a virulence factor upregulated by RNAIII following stimulation with AIP.
As shown in Figure 2B, the agr2 strain 502A produces abundant α-hemolysin, as
measured by rabbit erythrocyte lysis, in response to synthetic AIP2 which is attenuated
by the addition of VLDL or apoB to the culture. These data demonstrate that apoBcontaining lipoproteins antagonize AIP2-mediated upregulation of virulence factors in
vitro.
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Figure 2. Apolipoprotein B-containing Particles Antagonize agr2 and agr3 Signaling
and Virulence Factor Production
(A) Gene expression of RNAIII as measured by qRT-PCR in agr2 strain 502A (2 ×
108/ml) after exogenous stimulation with 10% overnight supernatant pre-incubated with
or without VLDL or apoB (2 μg/ml apoB each) for 30 minutes at 37°C and then grown
for 2 hours.
(B) Alpha hemolysin in supernatants from cultures of agr2 strain 502A (1 × 108/ml)
stimulated with 100 nM AIP2 and grown with or without VLDL or apoB (2 μg/ml apoB
each) for 6 hours as measured by a hemolytic assay.
(C) Alpha hemolysin in supernatants from cultures of agr3 USA400 strain MW2 (4 ×
107/ml) stimulated with 100 nM AIP3 and grown with or without VLDL (5 μg/ml) for 5
hours as measured by a hemolytic assay.
(D) Gene expression of psmα as measured by qRT-PCR in agr3 USA400 strain MW2 (1
× 107/ml) after exogenous stimulation with indicated AIP3 concentrations pre-incubated
with or without VLDL (5 μg/ml apoB) for 30 minutes at 37°C and then grown for 3
hours.
Data are represented as mean ± SEM; n = 2; * p < 0.1 ** p < 0.05 *** p < 0.02 as
compared to AIP-induced expression
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We next examined the ability of apoB-containing lipoproteins to antagonize
quorum sensing-mediated virulence factor expression in the clinically-relevant CAMRSA USAA400 agr3 strain MW2 (Baba et al., 2002). We first measured the ability of
VLDL to inhibit the production of α-hemolysin by MW2. Although in vitro MW2 does
not make appreciable amounts of α-hemolysin in response to synthetic AIP3, VLDL
inhibited α-hemolysin to the level of the broth control (Figure 2C). Next, we used qRTPCR to assess the ability of VLDL to inhibit expression of psmα, a gene target of
activated AgrA (Queck et al., 2008) and a direct readout of AgrA activation. As expected,
MW2 expressed psmα in response to exogenous synthetic AIP3. Message for psmα
peaked at 25 nM AIP3 but decreased at 50 nM, demonstrating that upregulation of psmα
in MW2 in vitro is mediated in a biphasic dose-response mechanism (Figure 2D).
Interestingly, it was only at the peak of psmα expression (at 25 nM AIP3) that VLDL
inhibition was observed and this inhibition, although significant, was moderate in relation
to the control of AIP1-induced RNAIII production we reported previously (Peterson et
al., 2008). These data suggest that apoB is minimally effective at antagonism of AIP3mediated virulence gene expression in vitro, and this is supported by the decreased
binding of AIP3 by apoB-containing lipoproteins demonstrated by SPR. Based on these
preliminary findings, apoB is able to interact with AIP2 to inhibit virulence in an agr2
strain of S. aureus in vitro whereas its control of AIP3 stimulated agr3 activation in strain
MW2 is greatly reduced.
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Mice with Pharmacologically-depleted Serum apoB are More Susceptible to agr2
but not agr3 S. aureus Infection
Apolipoprotein B is secreted from hepatocytes into the blood as a major structural
protein of VLDL particles and remains associated with the metabolized LDL particles
that circulate to the tissues for uptake by the LDL receptor (Shelness and Sellers, 2001).
Mice treated with the drug 4-aminopyrazolo-(3, 4-D) pyrimidine (4APP), have decreased
serum cholesterol, VLDL, and LDL levels due to inhibition of VLDL secretion from the
liver (Mounkes et al., 2001). To test whether apolipoprotein B is a mediator of host
defense against invasive S. aureus infections of the agr2 and 3 types, we used an air
pouch model of invasive infection to compare the responses of vehicle or 4APP-treated
C57Bl/6 mice. Subcutaneous injections of air create a pouch that becomes lined with
epithelium over 6 days, a model that has been used for both biofilm (Yoshikawa et al.,
2004) and invasive infection studies (Peterson et al., 2008; Rothfork et al., 2003;
Rothfork et al., 2004). In preliminary experiments, infection of 4APP-treated mice (black
bars) with early exponential phase agr2 bacteria 502A (Blair and Tull, 1969; Light et al.,
1967) at a dose easily tolerated by vehicle control mice (white bars) resulted in increased
morbidity, weight loss, and bacterial burden in the pouch lavage and spleen samples
(Figures 2A-C). Although only the morbidity score showed significant difference
between groups, the other parameters suggest a trend that low serum apoB levels
contribute to an exacerbated infection, and repeated experiments must be performed to
verify this conclusion. In contrast to mice exposed to agr2 strain 502A, mice receiving an
equivalent dose of MW2 (an agr type 3 strain (Baba et al., 2002)) showed no significant
difference in morbidity, weight loss or bacterial burden in the pouch lavage
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Figure 3. Effect of Depletion of Serum apoB by 4APP on agr2 502A infection and
agr3 MW2 (USA400) Infection
Mice were treated with 100 µl of 5 mg/ml 4APP or vehicle control (0.025M phosphate
buffer) (n=8 for each group for MW2 data, n=4 for each group for 502A data) i.p. 48 and
24 hours prior to infection of air pouches with either 7 × 107 MW2 USA400 or 8 × 107
502A. At 28 hours hrs post infection, the following parameters were determined and the
data represented as the mean ± SEM:
(A) Morbidity score 0-14.
(B) Weight loss
(C) Bacterial burden (Log CFU) in pouch lavage and spleen.
p < 0.05
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and spleen between 4APP and vehicle control treatment. These preliminary data suggest
that apoB-containing lipoproteins are important for controlling invasive infection in this
mouse model of infection an agr2 strain, but not an agr3 strain.

Discussion
Staphylococcus aureus has numerous mechanisms to resist host defense measures
as well as antibiotic treatment. The development of difficult-to-treat MRSA strains
emphasizes the need to develop better therapies that do not drive bacterial resistance. One
such method is to target virulence factors that contribute to disease but are not required
for bacterial survival (Alksne and Projan, 2000; Garcia-Lara et al., 2005). We have
previously shown that nature already utilizes this approach as demonstrated by
apolipoprotein B-mediated antagonism of S. aureus quorum sensing-dependent virulence
of agr1 strains (Peterson et al., 2008). Here we show preliminary data indicating that
virulence signaling in agr2 strains is also inhibited by apoB.
Apolipoprotein B specifically antagonizes one of the major S. aureus virulence
regulatory systems, agr, by binding to the signaling peptide AIP. In this work we present
preliminary data suggesting that this inhibitory action applies not only to agr type 1
strains, but to agr2 strains as well. ApoB binds to AIPs 1, 2, and 3, with maximal binding
between AIP2 and VLDL. In vitro studies show that apoB can greatly inhibit AIP2
downstream signaling events and is less effective against AIP3. Mice with reduced serum
apoB are less capable of controlling an agr2 infection, indicating the importance of serum
apoB for host defense against this strain. However, both vehicle and 4APP treated mice
infected with an agr3 strain were equally susceptible. The basis for this differential
protective effect of apoB is most likely due to the differences in AIP length. AIP3 is two
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amino acids shorter in length than AIP2, which seems to impact its ability to bind or
remain bound to apoB. These findings taken together may explain why agr3 strains cause
persistent bacteremia in patients more frequently than other agr types (Xiong et al.,
2009). When serum lipoproteins are unable to inhibit the induction of an invasive
phenotype, the bacteria can rapidly disseminate through the bloodstream. The robust
binding of apoB-containing particles to AIP2 and the subsequent apoB-mediated control
of type 2 invasive infection could explain the absence of agr2 USA100-caused disease in
the community setting (Limbago et al., 2009). Homeostatic levels of apoB, along with an
intact immune response, are sufficient for control of this type of S. aureus that normally
is found in hospital-acquired cases where the patient is already immunocompromised and
experiencing low levels of serum lipoproteins (Gui et al., 1996; Limbago et al., 2009;
Marik, 2006). This work highlights the phenotypic diversity among strains of S. aureus
which must be considered when developing or analyzing a potential clinical therapy:
even the host’s innate barriers have limits to their effectiveness and range of utility.
Apolipoprotein B is an important antagonist of S. aureus quorum sensing insofar as it can
bind and sequester the signaling peptide, as is the case in agr types 1 and 2 infections.
The shorter agr3 peptide is not well regulated by apoB-containing particles and as a
result is able to induce invasive infection that leads to systemic disease.
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CHAPTER 5
THE AMINO-TERMINAL DOMAIN OF APOLIPOPROTEIN B
BINDS STAPHYLOCOCCUS AUREUS AUTOINDUCING PEPTIDE
TO ANTAGONIZE INVASIVE INFECTION
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Introduction
Apolipoprotein B (apoB) is the large structural protein of serum low density and
very low density lipoproteins (LDL and VLDL, respectively); it initiates synthesis of
VLDL in the liver, interacts with the LDL receptor on cell surfaces to allow for uptake,
and recently was shown to antagonize virulence signaling in Staphylococcus aureus
(Mahley et al., 1984; Peterson et al., 2008). ApoB binds to a S. aureus signaling
pheromone peptide, AIP1, and sequesters it away from the bacterial receptor AgrC,
preventing virulence signaling. This function of apoB represents a unique barrier to
invasive infection that otherwise would result from AIP1 signaling. Polymorphisms in
apoB or truncated variants of the protein are known to exist among the human population
(Hooper et al., 2005; Tybjaerg-Hansen, 1995) and may affect the efficacy of this innate
barrier. Therefore, investigating the nature of the apoB-AIP1 complex and identifying the
domain of apoB that mediates this interaction is important for understanding human
susceptibility to invasive S. aureus infection.
Based on our previous in vitro observations that a monoclonal antibody directed
to the amino-terminus of apoB reversed apoB-mediated inhibition of S.aureus virulence
signaling as well as AIP1 binding to modified LDL particles (See chapter 3, Figures 1F,
3A, and 3D), we hypothesized that the N-terminal domain of apoB is responsible for
binding AIP1. This work aims to isolate a fragment of apoB that retains inhibitory
function that can then be characterized in terms of its structure, conformation, and
binding properties to AIP1.
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Results
Limited proteolysis of LDL generates fragments that retain inhibitory activity
Apolipoprotein B is a large (515 kDa) protein that is always associated with a
lipoprotein particle in vivo (Segrest et al., 2001). The pentapartite domain structure
consists of amphipathic alpha helices and beta sheets that span the bulk of the lipid
portion of the particle. Our first strategy to identify the inhibitory domain was to treat
apoB with proteases to generate fragments that still inhibited AIP-induced P3 promoter
activation and then to purify these fragments and characterize them. Both LDL and
VLDL are cleaved by several proteases into smaller fragments, and VLDL is more
resistant to proteolysis compared to LDL (Chen et al., 1989). In the context of either lipid
particle, the globular structure of apoB has three identified thrombin cleavage sites
(Figure 1A), as well as sites of cleavage for trypsin, S. aureus V8 protease, and pepsin.
The epitope for the monoclonal antibody C1.4, which reverses apoB-mediated
antagonism of AIP1 function, is located within the T4 thrombin cleavage fragment.
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Figure 1. Linear Protein Map of Apolipoprotein B
(A) A linear representation of ApoB 100. Percentage of length is shown below the map,
as well as the antigenic epitopes recognized by antibodies used in a S. aureus promoter
assay to rescue apoB-mediated inhibition of AIP1-induced P3 promoter activation.
Peptide sequences that later form secondary structures are color coded as indicated;
arrows above the map indicate cleavage sites confirmed by Chen and colleagues (Chen et
al., 1989), though numerous additional cleavage sites are predicted by the sequence.
Adapted from Pam Hall and Chen et al., 1989

89
We chose to utilize proteolysis to address two objectives: 1) to generate proteolytic
fragments sufficient for apoB antagonism of AIP1 function to allow for purification and
characterization and 2) to more definitively demonstrate that the lipid constituents of
VLDL and LDL plays purely a supporting role in AIP1 antagonism by maintaining the
conformation of apoB. We should be able to reverse the antagonism by digesting apoB
into sufficiently small fragments. We began by treating LDL with thrombin, trypsin, S.
aureus V8 protease, and pepsin, proteases whose cleavage of apoB has been well
documented to generate N-terminal fragments of varying lengths (Chen et al., 1989).
Following treatment and confirmation of cleavage by SDS-PAGE, the LDL was
incubated with early exponential phase cultures of the ALC1743 agr:P3-gfp reporter
strain, allowing us to analyze the degree of P3 promoter activation or inhibition by
measuring GFP fluorescence by flow cytometry. As expected, thrombin treatment did not
affect the ability of the LDL to inhibit P3 promoter activation (Figure 2A). Likewise,
LDL treated with trypsin, V8 protease, or pepsin also retained inhibitory activity.
However, pepsin treated LDL was slightly less effective at antagonizing AIP1 function.
As pepsin is expected to generate the shortest N-terminal fragment of apoB, it is possible
that the lack of significance of this single experiment is due to a mixed population
resulting from incomplete digestion. Further experiments using LDL digested with
increasing amounts of pepsin or for an extended time are warranted.
As the N-terminal region of apoB contains numerous disulfide bonds (Shelness
and Thornburg, 1996), we used the reducing agent dithiothreitol (DTT) in an effort to
expose additional protease cleavage sites otherwise protected in the globular structure.
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Figure 2. Effect of Protease and Lipase Treatment of Lipoproteins on ApoBmediated Inhibition of AIP1-induced Virulence Signaling
(A) agr:P3 promoter activation by 10 nM AIP 1 is inhibited in S. aureus (ALC 1743 with
agr:P3-gfp, 2×107/ml) during 3 hr of culture with LDL (2 μg/ml) or LDL treated with
proteases as follows: Thrombin (E:S 1:2) or thrombin vehicle for 2 hours at 37°C;
Trypsin (E:S 1:6) or buffer with or without reducing treatment (DTT for 1 hr followed by
Iodoacetamide for 3 hours at room temperature followed by buffer exchange) for 2 hours
at 37°C; V8 protease (E:S 3:1) or buffer with or without reducing treatment (DTT for 1
hr followed by Iodoacetamide for 1 hour at room temperature followed by buffer
exchange) for 3 hours at 37°C; Pepsin (E:S 1:300) or buffer for 1.5 hours at 37°C
followed by addition of pepstatin (equal molarity as pepsin) before inclusion in the assay.
Data are represented as percent activation of the P3 promoter as compared to AIP1
stimulation, and as the mean ± SEM; n = 3.
(B) VLDL inhibition of agr:P3 promoter activation induced by 10 nM AIP 1 in S. aureus
(ALC 1743 with agr:P3-gfp, 2×107/ml) during 3 hr of culture is rescued following
treatment of VLDL with lipoprotein lipase. VLDL (2 μg/ml) was incubated with (0.15
μg/ml) bovine lipoprotein lipase for 15 minutes at 37°C before added to cultures. LDL(2
μg/ml) treatment is included as a control. Data are represented as percent activation of the
P3 promoter as compared to AIP1 stimulation, and as the mean ± SEM; n = 3
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Combining reduction with trypsin digestion did not result in a significant change in the
ability of LDL to antagonize AIP1 function as measured by GFP fluorescence.
Surprisingly, the buffer and incubation conditions of the V8 protease treatment seemed to
enhance LDL inhibition of promoter activation, alter the bacterial response, or quench the
fluorescence of the GFP. These experiments may be enhanced by a thorough exchange of
the digest product into an inert buffer following digestion to avoid introducing artifacts to
the reporter assay. In addition, the reduction and digestion approach will be expanded to
include use of the pepsin protease as described above. Attempts to isolate active
proteolytic fragments via Protein G-agarose beads covalently coated with the C1.4
monoclonal antibody have been initially unsuccessful (data not shown). Future efforts to
isolate these active proteolytic fragments will include both ion exchange and size
exclusion chromatography.
As mentioned in Chapter 4, we previously noted that apoB, in the context of the
larger lipid particle VLDL, showed improved binding and functional antagonism of AIP1
compared to apoB in LDL. The conformation of apoB on VLDL differs slightly from the
conformation on LDL (Tsao et al., 1982). In our assays, LDL appears to bind and
functionally antagonize AIP1 similar to commercially available apoB purified from the
intact lipoprotein by ether extraction (US Biological, Swampscott, MA). The amount and
type of lipids remaining with the purified protein, if any, have not been determined, but it
is reasonable to expect that some lipids may remain since completely delipidated apoB is
reported to be insoluble (Fless et al., 1990). Based on these data and as an extension of
the objective to further address the role of the lipid particle as having a supporting role,
we treated VLDL with bovine lipoprotein lipase (LPL). Removal of lipids from the larger
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VLDL particle by LPL should reduce the diameter of the particle and result in a change
in apoB conformation similar to the apoB conformation in an LDL particle. Assessment
of VLDL before and after LPL treatment in the P3:GFP reporter assay resulted in the
treated VLDL particle being more “LDL-like” in its inhibitory capacity (Figure 2B).
Although this does not exclude a direct role for the lipoprotein lipids in AIP1 antagonism,
these data support the notion that the size of the lipid particle which carries apoB
contributes to the ability of apoB to antagonize AIP1.

Hepatocyte-derived amino terminal fragments of apoB retain inhibitory activity
As another approach to isolating amino-terminal fragments of apoB, we obtained
transfected rat hepatoma cells (McArdle- RH7777) that stably express and secrete fulllength or truncated forms of human apolipoprotein B in the context of an intact
lipoparticle (gift of Dr. Zemin Yao, Ontario) (White et al., 1992). This strategy ensures
that the protein is properly folded and associated with lipids in a physiologicallyappropriate conformation, unlike recombinant protein fragments alone (data not shown)
or artificial lipoprotein “particles” made by incubation of apoB with lipid emulsions
(Jiang et al., 2006).
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Figure 3. Fragments of Apolipoprotein B Produced by Stably Transfected McArdleRH7777 cells
(A) Linear protein map depicting the lengths of the ApoB fragments secreted by
transfected McArdle-RH7777 rat hepatoma cells. Peptide sequences that form secondary
structures are color coded as indicated.
(B) agr:P3 promoter activation by 10 nM AIP 1 is inhibited in S. aureus (ALC 1743 with
agr:P3-gfp, 2×107/ml) during 3 hr of culture with VLDL, LDL, or the McArdle apoB17
fragment (2 μg/ml apoB content each). Data are represented as the mean channel
fluorescence (MCF) of total S. aureus by flow cytometry, and as the mean ± SEM; n = 3
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We used McArdle cells expressing either the first 17% of the apoB protein
(apoB17) or the first 48% of the protein (apoB48, see figure 3A) to generate fragments to
use in our inhibition assays. Supernatants from the cells grown under serum-free
conditions for two days were collected, concentrated, selected for human apoB fragments
by pulldown with Protein G agarose beads covalently liked to monoclonal antibody C1.4,
and analyzed by SDS-PAGE before inclusion in the biological tests. The fragment
isolated from the apoB17 expressing cells antagonized the activation of the S. aureus P3
promoter as measured by flow cytometry (figure 3B). Further work must be done to
isolate fragment preparations of greater purity and to compare the inhibitory ability of the
different sized fragments.

The apoB-AIP1 interaction is pH dependent
Variations in interactions between binding partners in different pH environments
is to be expected as the surface charge of both molecules can greatly affect attraction or
repulsion at the protein:protein interface. This can be of importance in a physiologic
setting such as the low pH environment of a phagolysosome. In addition, binding
analyses performed under variable pH conditions has the potentially to reveal weaker,
secondary or alternate binding sites. To further investigate the nature of the binding
between apoB and AIP1, SPR was used to measure the binding of VLDL or purified
apoB to AIP1 at under different pH conditions. Binding as determined by the number of
RU generated, increased as pH was lowered from 7.4 to 5.8 (Figures 4A and B). These
data suggest that the site(s) of apoB binding to AIP1 contain amino acids whose charge
can be readily modified based on pH and, potentially, that the interaction between AIP1
and apoB would be enhanced in the acidic environment of the lysosome. In addition,
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since cyclic AIP can become linear at highly basic pH, it is possible that the cyclic AIP
structure is more stable at lower pH, thus contributing to enhance binding by apoB.
Clearly, these results require further investigation. We aim to continue this work by
kinetic evaluation of the AIP1-VLDL interaction under different pH conditions using
fluorescence polarization, a technique with which we have had recent success.

Discussion
The inhibition of AIP-induced virulence in S. aureus by apolipoprotein B
represents a newly described host innate barrier to invasive disease. The mechanism by
which apoB antagonizes AIP is only partially understood. Here we began investigations
to identify and characterize the AIP1 binding site within apoB. In these preliminary
studies, we demonstrate that apoB fragments generated here by proteolysis retain their
inhibitory activity, showing promise for fractionation and isolation of the specific
functional fragment. The ability of LPL to convert VLDL to an LDL-like inhibition
profile suggests a possible direct role for lipids in the lipoparticle-AIP1 interaction, and
also supports the notion that lipid induced conformational changes in apoB affect the
accessibility of the AIP1 binding site. Specifically, the conformation of the protein in
which it binds best to AIP may be dictated by its association with the lipid core. Finally,
our demonstration of enhanced binding of VLDL to AIP1 at lower pH suggests that the
binding site(s) contain residues whose charge is readily altered by changes in pH.
Together, these observations provide some insight into how apoB interacts with AIP1,
and will serve as the basis of future, more definitive experiments.
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Figure 4. pH Dependence of Apolipoprotein B-AIP1 interaction
(A) Surface Plasmon resonance analysis of whole VLDL particles binding to
immobilized AIP1 under different pH conditions shows greater binding response at lower
pH.
(B) SPR analysis binding between purified apoB and immobilized AIP1 under different
pH conditions. Greater binding response is observed at low pH.
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The ability of proteolytically cleaved apoB and supernatants of McRH7777 cells
expressing human apoB-17, although confounded by the presence of rat apoB, to
functionally antagonize AIP1 in our reporter assay may suggest that patients who have
truncated forms of apoB in their sera (such as those with familial
hypobetalipoproteinemia) may be at increased risk for invasive infection not because of
the truncated apoB, but because of their low apoB levels in general. Alternatively, these
patients may be more susceptible to invasive S. aureus infection due to the inability of
their truncated apoB-containing lipoproteins to be cleared by the LDL receptor (LDLR)
or other receptors that require the C-terminus of apoB for binding (Hooper et al., 2005;
Linton et al., 1993). This hypothesis will require more direct testing using suitable animal
models lacking specific receptors for clearance of apoB.
Further work that focuses on improved purification, measuring biological activity,
and describing the binding properties of generated fragments must be performed before
identification of the minimum inhibitory domain of apoB can be complete. The future
experiments most vital to understanding the mechanism of apoB binding to AIP are those
that aim to purify homogenous preparations of fragments so they can be compared in
their ability to bind AIP and inhibit downstream virulence signaling. Using more
sensitive techniques like ion exchange and size exclusion chromatography will greatly
improve the ability to not only interpret results but also to perform the right experiments
with appropriate controls. Besides identifying a minimum inhibitory protein fragment, it
will also be important to see if there is a minimum lipid component that is required for
inhibition, either by providing proper structure scaffolding for the protein, or by directly
interacting with the AIP after it is bound to the protein. In addition, if a lipid component
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is necessary for proper AIP-lipoprotein interaction, it will be necessary to identify the
type of lipid (triglyceride, phospholipid, cholesterol, or cholesterol esters) required for the
interaction. Our previous work showed that high concentrations of a triglyceride
emulsion could inhibit the ability of AIP to activate the quorum sensing promoter P3 (See
Appendix, Figure S2B), indicating that the triglyceride components of lipoprotein
particles may have some binding activity. Liposomes consisting of mixtures of
phospholipids and cholesterol, however, did not inhibit AIP-induced promoter activation
(See Appendix, Figure S2A). Based on these observations in addition to knowing that
VLDL has the greatest quantity of triglyceride content than any other lipoprotein, and it
elicits both the strongest AIP-binding and inhibiting responses as compared to LDL and
purified apoB, the triglyceride component may be important for the AIP1-VLDL
interaction. The role of lipids being important for a host defense mechanism of
lipoproteins has already been described in the context of HDL binding to LPS; however,
in the case of HDL, studies indicate that the phospholipid components of HDL are
responsible for this interaction that can provide protection from endotoxemia (Parker et
al., 1995). A similar approach to that taken by Parker and colleagues may be needed to
identify the type of lipid, namely, comparing AIP1 binding and inhibitory responses
elicited from particles formed from apoB combined with just one type of lipid.
Combining a number of different approaches as described here that address both the
protein and lipid aspects of apoB-containing particles will be necessary to fully define the
nature of the binding between apoB and AIP.
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CHAPTER 6
DISCUSSION AND CONCLUSIONS
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Summary and Future Directions
This work describes a role for the serum lipoprotein component apoB in providing
innate protection against invasive S. aureus infection. Apolipoprotein B antagonizes the
phenotypic switch in a S. aureus population from colonizing to invading by binding and
sequestering the quorum sensing peptide AIP away from its receptor AgrC. The absence
of apoB leads to invasive infection from both agr1 and agr2 strains in an animal model of
skin infection. The globular amino-terminal domain of apoB is responsible for binding
AIP via hydrophobic interactions with the thiolactone ring of the peptide. These
observations expand current knowledge regarding host defense against invasive bacterial
infection and the functions of lipoproteins beyond metabolism.
S. aureus has evolved numerous mechanisms to offset host defense. During the
immune response to S. aureus infection, neutrophils are recruited to the site and proceed
to phagocytose the bacteria for subsequent killing by antimicrobial peptides and reactive
oxygen species. Besides their antibacterial function, the ROS produced by neutrophils
also oxidize the bacterial signaling peptide AIP so it cannot function (Rothfork et al.,
2004). The mechanism of apoB antagonism of quorum sensing described in this thesis
acts as an additional barrier to AIP signaling that does not rely on the presence of
neutrophils or a functional NADPH oxidase. This barrier is also unaffected by the many
immune-evasion tactics employed by S. aureus to escape detection and killing which
target neutrophils’ mechanisms of host defense (see Chapter 1 figure 2). Although
bacterial proteases and lipases could alter host lipoprotein particles, expression of these
enzymes is regulated by the quorum sensing operon agr, so the action of apoB against
quorum sensing signaling could prevent its own degradation by bacterial factors.
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Several aspects of this apoB-mediated control of S. aureus virulence remain to be
elucidated. For example, the fate of the AIP-apoB complex is unknown. Specifically, it is
unclear whether sequestration of AIP by apoB is sufficient to maintain a protective
phenotype or if receptor-mediated clearance of the complex is required. In this regard,
scavenger receptors on macrophages could play a crucial role. Studies show that mice
deficient in the macrophage scavenger receptor CD36 are more susceptible to S. aureus
infection, though it is unknown if this is related to quorum sensing (Hoebe et al., 2005;
Stuart et al., 2005). Besides its normal metabolic function of removing modified LDL
particles from circulation, CD36 also recognizes bacterial diacylglycerides present in cell
wall components and can be a co-receptor with Toll-like Receptor 2 to sense microbial
pathogens. However, it may also act more directly to inhibit infection by removing AIPbound LDL during a quorum sensing-dependent infection. If this is the case, then CD36
knockout mice should be more susceptible to an agr+ infection but not an agr- infection
as compared to wild type mice. This subject is part of an ongoing investigation in our
laboratory.
Hypocholesterolemia is known to correlate with severity of illness due to sepsis
from multiple bacterial pathogens (Marik, 2006). One expansion of this work would be to
investigate the role of apoB in other bacterial infections, especially those that have
similar quorum sensing systems such as Enterococcus faecalis and S. epidermidis. In the
environment of the gut, apoB48 on chylomicrons may help to control quorum sensing
mediated by the cyclic E. faecalis pheromone GBAP (Nakayama et al., 2006). Like
MRSA, vancomycin resistant enterococcus infection is a growing problem, especially in
hospitalized patients (Chavers et al., 2003) and any understanding of host molecules that
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antagonize virulence could lead to important developments in treatment and therapeutic
options. ApoB may therefore have a role in host defense against other bacterial pathogens
beyond antagonizing S. aureus virulence signaling.
This work focuses on serum apoB as a specific barrier to S. aureus invasive
infection; however, other blood proteins exist that are already known to have antibacterial
or anti-virulence properties including complement, antibodies, C reactive protein, and
even hemoglobin, as has been recently described (Schlievert et al., 2007). From our own
experiments, even lipoprotein deficient serum has some activity against virulence
signaling, although the amount of apoB remaining has not been determined. Therefore,
other serum components must also be at work to limit invasive infection. Some
candidates we would suspect include HDL and albumin, since our own assays have been
influenced by the presence of these molecules in the experimental conditions. HDL is
known to bind both LPS and lipoteichoic acid, so it may be able to bind other bacterial
products as well. This may further support the idea that downregulation of HDL during
the acute phase response of infection is a good indicator of complication. Albumin is the
most abundant protein in the serum, so even if its anti-virulence properties are weak, its
sheer abundance could contribute to host control of bacterial virulence. Therefore, a
thorough investigation of the role of each of these serum components in antagonism of S.
aureus quorum sensing-mediated virulence is warranted.
Therapeutic application of this work is another possibility for development.
Providing lipid-rich nutritional support does not contribute to resolution of the acute
phase response or tolerance of invasive S. aureus infection (Marik, 2006; Hattie Gresham
and Jessica Mack, unpublished observation), but it is unknown if treatment with apoB or
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an apoB mimetic yet to be defined would be beneficial in models of local or invasive
infection or human cases. A pilot study using de-identified patient samples from the New
Mexico Veterans Affairs Health Sciences Center indicates that patients with invasive
MRSA infection have lower serum apoB levels compared to patients with localized
MRSA infections (Dr. Jon Femling, personal communication). These data indicate that
the protective effect of apoB seen in mice may apply to human infection as well;
therefore, treatment with exogenous apoB or apoB-containing particles may limit
infection and prevent dissemination. Animal studies that determine the best route of
administration, dosing, and time course will be necessary to demonstrate the feasibility of
the therapy before it can be proposed for human treatment.
An additional animal model of infection that is relevant to the abscess-forming
skin infections predominately seen in patients with MRSA is a dermonecrotic skin
abscess mouse model that is widely used in S. aureus virulence factor studies (Bubeck
Wardenburg et al., 2008; Voyich et al., 2006). This model would be very useful to
examine how well apoB extravasates with plasma to the site of infection. Interestingly,
the measurement of apoB in the skin is used as an indicator of coronary artery disease in
patient studies (De Graeve et al., 1984; Douste-Blazy et al., 1985), indicating that
measurable apoB would be present at the skin to limit agr-mediated virulence signaling,
allowing for innate immune effectors to clear the infection. This model would also be a
good method for the therapeutic development of apoB described above, since
administration of the apoB or apoB mimetic could be given directly into the infected site.
Another extension of this work would focus not on the host, but on elucidating the
relative resistance to apoB inhibition of quorum sensing in S. aureus agr3 strains. Based
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on genetic typing studies, it is theorized that agr groups began diverging from one
another about 55 million years ago to select for greater specificity in the agr locus, not as
a response to environmental pressures that could come from the host (Wright et al.,
2005). Since this agr diversification serves to isolate different groups one from another
instead of expanding virulence across sequence types, and the type 3 peptide seems to be
the most poorly bound by apoB, it appears that resistance of agr3 strains to apoB is an
evolutionary coincidence. The higher rate of bloodstream and menstrual toxic shock
diseases in agr3 infections as compared to agr1 and 2, could indicate another bacterial
mechanism of host evasion, a mechanism that is based simply on the length of the
bacterial AIP3 peptide. To address this hypothesis experimentally, a modified AIP3
peptide could be synthesized with two extra amino acids on the amino-terminal end, thus
making the peptide the same length as AIP2. The elongated AIP3 could then used in the
binding studies as measured by SPR and fluorescence polarization to determine if binding
to apoB-containing lipoproteins is improved over that of native AIP3. If the longer
peptide binds with greater affinity than the native peptide equal to that of AIP2, then it
can be concluded that peptide length determines the ability of apoB to control AIPmediated virulence, and by extension, why apoB cannot control bloodstream infections
with bacteria of the agr3 type.
In summary, much of the preliminary work described in this dissertation must be
expanded upon to reach definitive conclusions regarding the mechanism of apoB
inhibition of AIP signaling. First, the AIP binding of apoB must be defined. With this
information we can look at the polymorphisms of apoB found in the human population to
determine if any of those variations may directly or indirectly contribute to binding and
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proper conformation of apoB such that AIP antagonism is reduced or enhanced. These
polymorphisms may explain in part why some patients experience severe and
complicated infections where others have nothing more than a minor skin irritation. It
may also clarify why so many individuals can be colonized with S. aureus and not
succumb to invasive infection. Second, experimental determination of a Kd describing the
affinity of the interaction between apoB, either by itself or in the context of lipoprotein
particles, and the different AIPs should be accomplished. This would provide additional
information regarding the potential effectiveness of apoB as an innate protector against
invasive infection by S. aureus of different agr types. One method of generating this data
is fluorescence polarization, whereby a small fluorescent molecule initially depolarizes
light until it is immobilized by a larger binding partner, allowing the light to remain
polarized. Fluorescence polarization may be a better tool to measure binding affinity than
SPR because it does not rely on immobilization of one of the binding partners, should be
unaffected by the tendency of lipoproteins to adhere to surfaces, and will not be affected
by the differences in size between whole lipoprotein particles and apoB alone. In
addition, it may be more beneficial for examining the function of the amino terminal tail
relative to the thiolactone ring for AIP interaction with apoB. Finally, a prospective study
of serum apoB levels and apoB polymorphisms in patients at risk for S. aureus infection
will be needed to ascertain whether what we have demonstrated in our mouse model of
invasive infection has a clinically relevant human correlate.

Conclusions
The data and interpretations presented in this manuscript describe the role of
apolipoprotein B as a specific inhibitor of S. aureus virulence, the efficacy of this
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inhibition among different agr types of S. aureus, and the mechanism by which the
inhibition is mediated. As the incidence of CA-MRSA infections continues to increase, it
will become more vital to understand host factors that are important for limiting
infection, including factors that may be lacking in populations of otherwise healthy
individuals. The demonstration of apolipoprotein B-mediated control of S. aureus
virulence in this dissertation is one example of a host defense mechanism that is
important for control of CA-MRSA infections. The data herein specifically show that
apoB is effective against agr type1 strain USA300, a CA-MRSA clone that has spread
globally, replacing endemic CA-MRSA strains (Diep and Otto, 2008). Though this strain
produces a number of virulence factors in abundance, its rapid dissemination is attributed
to its fitness for transmission in the human population. Historical and current strategies
for treating S. aureus and other bacterial diseases have emphasized limiting growth,
which has promoted the development of bacterial resistance. New methods that still curb
severe disease without contributing to drug resistance are necessary to effectively manage
cases of S. aureus infection. As we continue to study the role of apoB in limiting invasive
infection, therapeutic measures can be developed to combat USA300 disease by
enhancing the body’s own anti-virulence methods. Apolipoprotein B-mediated control of
invasive S. aureus infection provides a new way of looking at the management of
bacterial disease by focusing on inhibiting virulence rather than growth.
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APPENDIX
Supplemental Figures to Chapter 3

Figure S1. Effect of Serum Lipoproteins on Spontaneous agr:P3 Promoter
Activation by Serum
(A) ALC1743 (non-fluorescent, early exponential phase, 2.0 × 107/ml)) were cultured in
90% TSB and 10% either pooled human serum (PHS) or 10% lipoprotein deficient
pooled human serum (PHS) at 37°C with shaking. To prevent clumping, the samples
were sonicated on ice at 30 min intervals. At the indicated times, the bacteria were plated
for CFU determination and washed and fixed for flow cytometry to determine GFP
induction. Spontaneous agr:P3 promoter activation is significantly enhanced in the
presence of LPDS vs PHS after 5 and 7 hrs of culture whereas bacterial CFU is
unaffected. Data are represented as the mean ± SEM, n=2 performed in duplicate.
(B) ALC1743 (non-fluorescent, early exponential phase, 3.5 × 107/ml) were cultured in
90% TSB and 10% PHS (pretreated with either 10 µg/ml murine IgG1 or murine IgG1
anti-apoB N-term mAb C1.4 on ice for 30 min) for 3 hr at 37°C with shaking. To prevent
clumping, the samples were sonicated on ice at 30 min intervals. At the indicated times,
the bacteria were washed and fixed for flow cytometry to determine GFP induction.
Spontaneous agr:P3 promoter activation is significantly enhanced in the presence of anti-
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apoB treated PHS vs. the isotype control treated PHS after 3 hrs of culture. Data are
represented as the mean ± SEM, n=2 performed in duplicate.
(C) USA300 LAC wild-type (early exponential phase, 3.5 × 107/ml) were cultured in
90% TSB and 10% PHS (pretreated with either 10 µg/ml murine IgG1 or murine IgG1
anti-apoB N-term mAb C1.4 on ice for 30 min) for 3 hr at 37°C with shaking. To prevent
clumping, the samples were sonicated on ice at 30 min intervals. At the indicated times,
RNA was extracted and RNAIII quantified relevant to 16S RNA by qRT-PCR as
described in the Materials and Methods.
RNAIII transcript levels are significantly increased in the presence of anti-apoB treated
PHS vs the isotype control treated PHS. Data are represented as the mean ± SEM, n=2
performed in triplicate.
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Figure S2. Effect of Liposomes and Triglycerides on AIP-Dependent agr:P3
Promoter Activation
(A) Incubation of AIP1 with liposomes containing stearylamine (10 mM
phosphatidylcholine, 1.5 mM cholesterol, 3 mM stearylamine), phosphatidylcholine (PC,
10 mM), or phosphatidylcholine/free cholesterol (PC/FC, 7.1mM/2.9mM) did not inhibit
AIP1-dependent agr:P3 promoter activation as compared to LDL. Data are represented as
the mean ± SEM, n=2 performed in triplicate.
(B) Supernatants from overnight cultures of lipase-producing (agr+ and NM300) or
lipase-nonproducing (agr- and lipase-) strains were incubated with a 0.5% solution of the
triglyceride tributyrin (5x normal serum levels) prior to incubation with AIP1 to test in
the agr:P3-gfp reporter assay. Tributyrin inhibition could be reversed by lipase whereas
VLDL inhibition was not reversed by bacterial lipase. Data are represented as the mean ±
SEM, n=2 performed in duplicate.

110

Figure S3. Virulence Factor Production Suppressed by Lipoproteins
(A) Apolipoprotein B inhibited in a dose-dependent fashion AIP1-induced hla promoter
activation. S. aureus ALC 1740 containing an hla-gfp plasmid was cultured with 100 nM
AIP1 with or without increasing concentrations of purified apoB. After 6.5 hours,
promoter activation was measured by flow cytometry. Data are represented as the mean ±
SEM, n=3.
(B) Alpha hemolysin in culture supernatants generated by growing bacteria in the
presence of 100 nM AIP1 (synthetic or partially purified from culture supernatant by size
exclusion) with or without 8 µg/ml apoB for 6.5 hr was measured in a hemolytic assay.
SH1000 is a sigma B corrected variant of RN6390, FPR 3757 is a MRSA USA 300
PFGE clinical isolate, and NM 400 is an agr group 3 MRSA USA 400 PFGE clinical
isolate. Data are represented as the mean ± SEM, n=3.
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(C) Inhibition of spontaneous alpha hemolysin production by two MRSA USA300
strains, UAMS1378 and LAC, after 6.5 hr of culture in the presence and/or absence of
purified apoB. Data are represented as the mean ± SEM, n=2 performed in duplicate.
(D) Lipase in culture supernatants generated by culturing NM300 (MRSA USA 300
clinical isolate) with 100 nM AIP1 with or without apoB (5 µg/ml) for 7 hr was measured
by the rate of cleavage of a triglyceride substrate (tributyrin) assessed at OD450 nm.
Values are compared to the supernatant of a lipase deficient strain. Data are represented
as the mean ± SEM of duplicates and are representative of at least 3 separate
experiments.
(E) Lipase in culture supernatants from MRSA USA300 LAC cultured in the presence of
100 nM AIP1 with or without VLDL (2 µg/ml) was measured as in (D). Data are
represented as the mean ± SEM of duplicates and representative of two separate
experiments.
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Figure S4.Binding of Apolipoprotein B and AIP1 by Surface Plasmon Resonance
(A) Biacore X100 sensorgram of the interaction of apoB (0.25-10 nM) with biotin-AIP1
immobilized on a streptavidin chip following the manufacturer's protocol. Kinetic data
were collected at a flow rate of 30 µl/min in running buffer with a contact time of 60 s
and dissociation over 300 s. Data are representative of 3 separate experiments.
(B) Native AIPs (1, 2, &4), modified AIPs (linear AIP1, oxidized AIP1, and Y-AIP3), or
a control cyclic peptide made by disulfide cross linking (all at 50 nM) were mixed with
10 nM apoB prior to injection onto immobilized biotin-AIP1 at a flow rate of 10 µl/min
with a contact time of 60 s followed by a 60 s dissociation time. The resulting resonance
units were analyzed as a percentage of the resonance units of apoB binding in vehicle
control. Data are represented as the mean ± SEM, n=3-4. *p<0.001.
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Figure S5. Effect of agr on S. aureus Infection of NADPH Oxidase Knockout
(gp91phox-/-) Mice Treated with 4APP
Mice were treated with 100 µl of 5 mg/ml 4APP or vehicle control (0.025M phosphate
buffer) (n=8 for each group) i.p. 48 and 24 hours prior to infection of air pouches with
either 7 × 106 (agr:P3-gfp, ALC 1743, or Δagr:P3-gfp, ALC 1753). At 28 hours hrs post
infection, the following parameters were determined and the data represented as the mean
± SEM:
(A) Weight loss.
(B) Morbidity score 0-14.
(C) Bacterial burden (Log CFU) in pouch lavage and spleen.
(D) Quantification of agr:P3-gfp promoter activation by flow cytometry of bacteria
isolated from the pouch lavage.
(E) Representative pouch tissue from the mice stained with anti-S. aureus antibody (red
fluorophore). Quorum-sensing S. aureus are visible by production of GFP in the pouch.
(F) Quantification of bacterial density in epidermis and dermis of pouch tissue
demonstrating significantly greater bacterial density of agr+ bacteria but not agrbacteria and greater quorum sensing in 4APP-treated mice from at least 19 representative
areas. L = lumen D = dermis E = epidermis
Arrows indicate point of greatest penetration by quorum sensing bacteria
* p < 0.05 ** p < 0.01
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Figure S6. Effect of agr on MRSA USA300 S. aureus Infection of NADPH Oxidase
Knockout (gp91phox-/-) Mice Treated with 4APP
Mice were treated with 100 µl of 5 mg/ml 4APP or vehicle control (0.025M phosphate
buffer) (n=8 for each group) i.p. 48 and 24 hours prior to infection of air pouches with
either 2.5 × 107 USA300 UAMS1378 or Δagr UAMS1540). At 28 hours hrs post
infection, the following parameters were determined and the data represented as the mean
± SEM:
(A) Morbidity score 0-14.
(B) Weight loss.
(C) Bacterial burden (Log CFU) in pouch lavage and spleen.
(D) Representative pouch tissue from the mice stained with anti-S. aureus antibody (red
fluorophore).
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